annual report live goal live n n v n live c r e living r e p n b l living n e p e n e n c e value innovationcontent company p product portfolio p shareholders perspective brand prescription key aspect medicine corporate body respiratory disease highlight medicine cardiovascular disease live innovation metabolic disease live care oncology living responsibility disease central live independence nervous system infectious disease consumer health care cough cold group management p sore throat report pain gastrointestinal disease information vitamin supplement group companies leg vein health report economic position urological disease report postbalance sheet date event animal health risk report food produce animal report expect swine development food produce animal poultry food produce animal consolidate p financial statement cattle companion animal overview major horse consolidated company companion animal consolidate balance sheet small animal consolidated profit loss statement cash flow statement statement change group equity note consolidated financial statement auditor reportlive goal annual report live innovation p living care p living responsibility p live independence p tnetnocboehringer ingelheim group financial highlight amount million eur indicate change net sale region europe americas asia australia africa business prescription medicine consumer health care animal health biopharmaceutical industrial customer sale research development personnel cost average number employee operate income operating income net sale income taxis income taxis net sale shareholder equity return shareholder equity cash flow investment tangible asset depreciation tangible asset product prescription medicine product consumer health care net sale million eur change net sale million eur change spiriva buscopan micardis dulcolax pradaxa mucosolvan combivent pharmaton v company boehringer ingelheim group world lead ing pharmaceutical company headquarter ingelheim germany boehringer ingelheim operate globally af filiate total employee focus familyowned company found research develop manufacturing marketing new medication high therapeutic value human veterinary medicine take social responsibility important element corporate culture boehringer ingelheim include worldwide involvement social project initiative make health care employee respect equal opportunity reconcile career family form foundation mutual cooperation company focus environmental protection sustainability shareholder perspective shareholder perspective christian boehringer chairman shareholders committee shareholder family boehringer ingelheim determine path company take give continue support year create sound financial structure commit provide longterm strategy offer prerequisite sta bility profitability sustainable growth founder com pany albert boehringer lay foundations w e dedicated chapter live independence annual report independence paramount objective reason firmly anchor understand boehringer ingelheim company stand innovation care responsibility include excellent example annual report research scientist boehringer ingelheim annual report business year shareholder perspective research institute molecular pathology vienna sup port boehringer ingelheim patient australia employee italy actively involve boehringer ingelheim social project value mean shareholder innovation driver growth company right start true vision value innovation begin pro duction tartaric lactic acid follow medicine research department set boehringer ingel heim pioneer field biopharmaceutical today pharmaceutical product portfolio therapeutic area respiratory disease cardiovascular disease metabolism oncology disorder central nervous system immunology year planning launch new medicine treatment widely differ indication success unthinkable intense research development year place high value collaboration external partner field science industry frequently relatively small biotechnology firm provide platform transfer knowledge expertise party benefit example include collaboration research institute molecular pathology imp vienna scientific collaboration university dresden collaboration firm circuit thera peutic california guiding principle research development work meet medical need patient goal supply medicine help provide new effective efficient therapy option mean speak care ethical company focus medicine high sale potential carry r esearch medicine treatment rare disease example possible compound nintedanib treatment idiopathic pulmonary fibrosis aml rare form leukaemia currently test compound volasertib shareholders perspective fundamental aspect assume responsibility people limit corporate activity boehringer ingelheim social responsibility commitment society facet integral corporate philoso phy begin example compound nevirapine prevention hiv transmission mother child birth available free charge develop country year possible generic manufacturer pro duce market nevirapine demand licence fee way help ensure availability medicine combat hiv aid long price issue make health initiative work nonprofit organisation ashoka promote sustainable health initiative worldwide end make health support social entrepreneur healthcare field globe search new well way improve health help people obtain easy access medical solution live matter responsibility everyday work way deal company characterise mutual respect responsibility individual contribute po sition create value innovation accept responsibility action true thing go times difficult see financial year end easy year complaint food drug administration fda quality assurance process ingelheim present major challenge member staff subsequently exceptional job establish prerequisite followup inspection short time remain occupied revision optimisation quality system year ahead boehringer ingelheim annual report business year key aspect like thank member staff board manage director course great commitment effort company look year report please nature successfully enter therapeutic area oncology develop field diabete respiratory disease new product add animal health consumer health care overall create basis ensure continue longterm success certain challenging year cer tainly look forward confidence future boehringer ingelheim position master challenge continue work successfully live goal attain supreme goal independence familyowne company sign christian boehringer chairman shareholders committee key aspect key aspect allan hillgrove joachim hasenmaier andreas barner hubertus von baumbach wolfgang baiker leave right board manage director look previous financial year different angle hand see local viewpoint grow albeit moderately com parison previous year increase result absolute term profi tability distinctly despite force absorb considerable negative currency effect hand easy year boehringer ingelheim reason include complaint quality assurance process production facility ingelheim food drug administration fda close facility bedford ohio fact growth weak comparison previous year result increasingly difficult market environment europe example usa japan view challenge year transition boehringer ingelheim boehringer ingelheim annual report business year decisive factor boehringer ingelheim entire workforce able face challenge successfully necessary change lie foundation positive development year ahead achievement research development research development large number achievement par ticularly expand product portfolio compound afatinib successfully enter field oncology addition diabete second new therapeutic area boehringer ingelheim afatinib target treatment lung cancer market gilotrif launch begin european union novel oncology compound nintedanib phase iii clinical trial show treatment lung cancer combination chemotherapy extend life patient adenocarcinoma initial treatment fail year field diabetes successfully complete key phase iii trial com pound empagliflozin submit application international marketing authorisation expect receive initial authorisation market launch year delight success field respiratory disease result phase iii trial involve patient chronic obstructive pulmonary disease copd show olodaterol respimat addition current standard treatment exception longlaste beta agonist lead statistically sig nificant improvement lung function olodaterol approve use brand striverdi respimat time submission medicine therapeutic area currently schedule pharmaceutical research development setback possible final straight experience recently interferonfree combination hepatitis c compound faldaprevir deleobuvir live expectation preliminary evaluation phase iii trial december show reason decide terminate development deleobuvir expect receive initial approval interferonbase programme faldaprevir end year examine activity field hepatitis c therapy depth view convince clinical datum competi tor field key aspect research development secure future portfolio medicine future business success year planning introduce new product indication diabete copd asthma lung cancer idio pathic pulmonary fibrosis ipf rare form leukaemia aml addition treatment prevention deep vein thrombosis pulmonary embolism research development overall currently work project year expenditure project million euro remain high level equivalent cent net sale people employ research development boehringer ingelheim key growth driver pradaxa despite continue difficult market environment achieve currency adjust growth net sale low singledigit range take account negative currency effect result cent decline net sale compare previous year growth driver prove oral anticoagulant pradaxa net sale rise cent million euro net sale million euro spiriva treatment copd bestselle product previous year able increase operating income cent million euro result improve return net sale cent show successful offsetting extraordinary factor negatively affect result implement initiative year design increase efficiency reduce cost include situation ben venue production facility sterile injection solution spite major effort undertake return future compatible stable production possible particu larly market environment change considerably facility closed end year extensive reorganisation production pro cesse ingelheim preparation followup inspection food drug administration affect result market situation medicine change rapidly worldwide remain impor tant continuously examine internal structure process decisive question improve optimise way respond customer need background restructure regional business operation revise strategy therapeutic area strengthen organisation boehringer ingelheim annual report business year market access innovative medicine increasingly difficult view age population health system worldwide face chal lenge continuously increase cost undergo sustained change hand increase demand innovative medicine long term help relieve burden place system provide effective alternative therapy hand financial budgetary demand health system increase short term immediate impact budget pharmaceutical product challenge industry short term long term present great opportunity strike example shortterm challenge germany new law result substantial cut pharmaceutical company involve research difficult bring medicine research produce germany german market reason difficult decision offer trajenta medicine treatment diabetes germany add benefit medicine reject place medicine meantime approve country german market price justify expect extensive clinical trial necessity place approval give demonstrate distinct add benefit damage research company germany situation inconsistent economic importance boehringer ingelheim germany growth boehringer ingelheim gross value add germany time high german economy datum pub lishe independent economic research institute wifor show socalled health satellite account outlook continue difficult market environment impact patent loss large number market usual industry mean expect face chal lenge view situation expect net sale current fi nancial year level comparable achieve boehringer ingelheim launch new medicine intend introduce market year year ahead foreground activity key aspect priority current financial year order lie foundation future growth continue focus effort year intend drive growth forward business area give priority cost awareness efficiency need customer guide principle action quality compliance word strict adherence establish rule regulation give high priority production clear commitment transparency openness apply figure clinical test trial company like boehringer ingelheim live large degree expertise experience commitment entire workforce deserve special thank particularly view challenging year continue place trust confidence active support loyalty lie foundation year enable company growth path signed sign andreas barner wolfgang baiker signed sign hubertus von baumbach joachim hasenmaier sign allan hillgrove boehringer ingelheim annual report business year corporate body corporate body shareholder committee board manage director christian boehringer prof dr dr andreas barner chairman shareholders committee chairman board corporate board division human resource christoph boehringer research development medicine erich von baumbach jr dr wolfgang baiker isabel boehringer corporate board division operation dr mathias boehringer biopharmaceutical hubertus von baumbach advisory board corporate board division finance prof dr michael hoffmannbecking prof hc dr wolfram carius corporate board division operation attorney law dsseldorf biopharmaceutical chairman advisory board dr joachim hasenmaier egbert appel corporate board division animal health trustee martin hilti family trust consumer health care president hilti foundation chairman advisory board allan hillgrove corporate board division kurt beck pharma marketing sale ministerpresident dr andreas kreimeyer member board executive director research executive director basf se jan rinnert chairman board management chief financial officer heraeus hold gmbh republic austria highlight medicine highlights medicine new product market new substance submit registration new study result publish successful year continue individual market pradaxa boehringer ingelheim term launch submis treatment dvt pe striverdi respimat sion new biological chemical entity company boehringer ingelheim submit registration individual market launch giotrif indica documentation europe tiotropium asthma tion nonsmall cell lung cancer nsclc pradaxa diabetes alliance boehringer ingelheim treatment prevention deep vein thrombosis eli lilly company submission empagliflozin dvt pulmonary embolism pe receive adult type diabete new insulin european approval striverdi olodaterol respimat glargine product type type diabetes chronic obstructive pulmonary disease copd file boehringer ingelheim enter new therapeutic company continue successful path renew area faldaprevir hepatitis c late expand product portfolio manage commence registration process novel compound boehringer ingelheim second oncology product nintedanib nsclc registration process overview important boehringer ingelheim authority start additional registration process clinical study metabolism linagliptin trajenta linagliptin carmelina trial investigate effect result datum highly relevant receive placebo adverse event see linagliptin versus standard care cardio treatment selection patient recruit linagliptin occur comparable vascular renal microvascular event ment carolina accomplished frequency placebo study group consist adult november significant difference compare placebo type diabete risk cardiovascular term hypoglycaemia patient renal event patient enrolment start receive concomitant treatment treatment elderly type diabetes patient july know increase risk hypoglycae complex challenge datum mia insulin phase iii study publish lancet ongoing carolina study august show blood glucose eventdriven headtohead cardiovascular level elderly people type diabetes outcome trial compare dpp inhibitor follow week treatment linaglip linagliptin sulfonylurea glimepiride tin drop significantly compare boehringer ingelheim annual report metabolism empagliflozin end half international diabetes congresse number pivotal study investi addition enrolment trial pro gational agent empagliflozin finally gramme complete july complete phase iii clinical trial pro empareg outcome trial eventdriven gramme empareg empagliflozin cardiovascular endpoint study evaluate member sodium glucose cotran effect empagliflozin versus standard treat porter sglt inhibitor class drug ment people type diabetes programme focus type diabete high cardiovascular risk boehringer enrol patient com ingelheim confident large datum set empagliflozin prise multinational clinical convince authoritie registration trial key study datum release process cardiovascularvascular disease pradaxa clinical trial boehringer ingelheim expand clinical development programme pradaxa dabigatran etexilate pin continue leadership commit ment innovative solution benefit patient physicians worldwide dabigatran etexilate remedy resonate future antidote recover commitment development key finding clinical trial addition boehringer ingelheim con boehringer ingelheim permanently commit contribute regulatory submission tinue gather realworld clinical data ted patient safety context com pradaxa treatment acute patient nonvalvular atrial fibrillation pany develop specific highly selec prevention dvt pe subse undertake research use tive humanise antibody fragment provide quent secondary prevention result pradaxa new cardiovascular patient popu physicians rare emergencies addi remedy recover resonate lation end company tional option halt anticoagulant effect publish prestigious journal announce new phase iii study pradaxa new england journal medicine plan respect esus research circulation conduct safely initial result study healthy test pradaxa prevent stroke person phase clinical study patient initial stroke cause result demonstrate efficacy favoura potential antibody fragment fab blood clot unknown origin redual pci ble safety profile pradaxa impor specific antidote halt anticoagulant investigate safely pradaxa tant area unmet medical need effect dabigatran immediately completely prevent blood clot patient atrial last basis fibrillation coronary stent implant narrow blood vessel highlight medicine oncology hepatitis c virus afatinib faldaprevir giotrif afatinib june boehringer ingelheim pre nonsmall cell lung cancer nsclc sente datum luxlung phase iii positive egfr erbb mutation status trial show cent demonstrate treatment patient receive giotrif afatinib giotrif patient type faldaprevir tumour progressionfree year lung cancer lead significant delay treatment compare cent tumour progression improvement patient chemotherapy diseaserelate symptom like short result present ness breath cough chest pain boehringer ingelheim startverso phase iii improve quality life new result confirm finding programme investigate faldaprevir company previous phase iii trial lux combination pegylate interferon lung compare afatinib different giotrif approve authority ribavirin hepatitis c patient geno chemotherapy regimen pemetrexedcisplatin european union number addi type difficult genotype treat result giotrif superior com tional country usa register trial programme investigate treatment pare standard chemotherapy patient brand gilotrif nave patient startverso treatment experience patient startverso hiv coinfecte patient startverso overall study encompass patient faldaprevir prove safe efficacious patient infect genotype hepatitis include advanced liver disease cent pre nintedanib viously untreated patient early treatment success achieve enable short treatment duration furthermore oncedaily administration dietary restriction compound offer simple convenient option current nintedanib standard treatment end company submit result lumelung phase iii involve angiogenesis tumour growth faldaprevir registration food clinical trial novel investiga importantly patient benefit addi drug administration fda european tional compound nintedanib lung tional efficacy nintedanib medicine agency ema authori cancer treatment combine impair quality life tie worldwide chemotherapy extend survival year patient initial therapy basis result boehringer fail early patient firstline ingelheim submit nintedanib euro therapy fail great benefit pean medicine agency regulatory nintedanib provide compare control agency second half group nintedanib oral triple angiokinase inhibitor target receptor crucially boehringer ingelheim annual report respiratory disease tiotropium tiotropium spiriva respimat asthma spiriva handihaler cent asthma patient tiotropium safety performance study spiriva handihaler suffer symptom despite currently avail respimat tiospir global landmark trial survival advantage show com able treatment option experience patient pare control therapy tiospir asthma exacerbation attack gratify large chronic obstructive pulmonary trial population select broad inclusion new datum tiotropium asthma prove disease copd trial conduct criterion representative typical copd tiotropium respimat effective sympto compare spiriva respimat dose patient present daytoday practice matic asthma patient irrespective spiriva handihaler g result include patient copd disease allergic status age smoking habit publish er congress sep severitie comprehensive use con bronchodilator response tiotropium tember simultaneously new comitant copd medication patient administer daily respimat signi england journal medicine medical history cardiac disorder ficantly improve lung function datum form basis submis sion approval spiriva respimat furthermore similar impact survival usa primotinaasthma study demonstrate spiriva respimat doubleblind parallelgroup trial include spiriva handihaler tiospir trial asthma patient show symptom important early uplift despite treatment inhale corti costeroid icslongacte betaagonist laba total patient ran domise additional therapy tiotro pium respimat placebo weeks tiotropium reduce asthma exacerbation olodaterol patient retain symptom despite treatment ics laba irre spective allergic status datum mezzotinaasthma phase iii striverdi respimat twin study present time european respiratory society er congress confirm statistically signifi not clinically relevant improvement result phase iii study present lung function improvement hour asthma control oncedaily tiotropium medical congress barcelona spain combination usual therapy medi provide patient continue september show cine rapidly take effect minute symptom despite treatment ics patient olodaterol respimat dose lung function improvement addition usual care provide statistically oncedaily olodaterol respimat result registration process tiotropium significant improvement lung function copd patient achieve meaningful asthma start eu second improvement quality life usual half olodaterol highly selective longacting care betaagonist laba boehringer ingelheim research pipeline oncedaily olodaterol receive registration administer olodaterol respimat maintain brand striverdi respimat follow luisa cochella occupation group leader nose research institute molecular pathology imp year birth location vienna austria innovation mean are face un know go go luisa cochella colleague involve worm identify cell take vision course groundbreake work scientist act molecular biologist involve type persever research institute molecular pathology imp microrna research course luisa ance vienna carry research determine wants prepare comprehensive confused happen molecular level cell model microrna process round stubbornness divide cancerous tumour develop worm role microrna play development organism imp largely sponsor potential use oncology boehringer ingelheim carry basic work eventually help development research completely independent basis new type medicine microrna oncology biomarker example buenos aire vienna detect tumour include medicine luisa typical representative lead inhibit growth tumour internationally renowned research institute important cell differentiation bear buenos aire argentina study possibly cultivate tissue trans usa dutch partner plantation vision far luisa molecular biologist move vienna grateful boehringer ingelheim head fivemember international imp sponsor farsightedness team research scientist undertake basic research place characterise truly innovative company imp conduct research work say biologist microrna roundworm c elegans scien tist discover short ribonucleic acid mole ensure information cule microrna consist practical use lose imp research scientist nucleotide present virtually hold regular meeting exchange view multicellular organism year ago information boehringer ingelheim microrna ensure example cell meet example joint symposium divide uncontrolle manner hold year year topic different cell type body develop microrna medical application say luisa fertilise egg proudly possible worms fluorescent sensory neuron help understand detail luisa exchange drug developer come bright new gene switch individual microrna idea wait worm change isolate microrna follow luisa cochella occupation group leader nose research institute molecular pathology imp year birth living n n v n location vienna austria innovation mean are face un know going boehringer ingelheim carry research new disease develop go luisa cochellan aenwd dherur cgosl laenagdu tehs earrae pinievsol viendn ovatiionn th eth weorremfo arne iisd evnittaifil efdo ri not hweh ficuht ucreell tfh tehy e take vision course groundbreake work scientist act molecular biologist involve company mean boehringer ingelheim rely research type persever research institute molecular pathology imp microrna research course luisa development place great emphasis collaboration ance vienna carry research determine wants prepare comprehensive confused happen wati tthhe e mxtoelercnualla pr laervtenl ewrsh en fcreolmls acadmeomdeicl oinf asltli tmuitcerso rannda bpiroocpehsasersm ina ctheeu rtoicuanld stubbornness divide cancecroomusp taunmioeusr tso esvtaelrotpu apnsd worm role microrna play development organism imp largely sponsor potential use oncology boehringer ingelheim carry basic work eventually help development research completely independent basis new type medicine microrna oncology biomarker example buenos aire vienna detect tumour include medicine luisa typical representative lead inhibit growth tumour internationally renowned research institute important cell differentiation bear buenos aire argentina study possibly cultivate tissue trans usa dutch partner plantation vision far luisa molecular biologist move vienna grateful boehringer ingelheim head fivemember international imp sponsor farsightedness team research scientist undertake basic research place characterise truly innovative company imp conduct research work say biologist microrna roundworm c elegans scien tist discover short ribonucleic acid mole ensure information cule microrna consist practical use lose imp research scientist nucleotide present virtually hold regular meeting exchange view multicellular organism year ago information boehringer ingelheim microrna ensure example cell meet example joint symposium divide uncontrolle manner hold year year topic different cell type body develop microrna medical application say luisa fertilise egg proudly possible worms fluorescent sensory neuron help understand detail luisa exchange drug developer come bright new gene switch individual microrna idea wait worm change isolate microrna follow nose luisa cochella colleague involve worm identify cell groundbreake work scientist act molecular biologist involve research institute molecular pathology imp microrna research course luisa vienna carry research determine wants prepare comprehensive happen molecular level cell model microrna process round divide cancerous tumour develop worm role microrna play development organism imp largely sponsor potential use oncology boehringer ingelheim carry basic work eventually help development research completely independent basis new type medicine microrna oncology biomarker example buenos aire vienna detect tumour include medicine luisa typical representative lead inhibit growth tumour internationally renowned research institute important cell differentiation bear buenos aire argentina study possibly cultivate tissue trans usa dutch partner plantation vision far luisa molecular biologist move vienna grateful boehringer ingelheim head fivemember international imp sponsor farsightedness team research scientist undertake basic research place characterise truly innovative company imp conduct research work say biologist microrna roundworm c elegans scien tist discover short ribonucleic acid mole ensure information cule microrna consist practical use lose imp research scientist nucleotide present virtually hold regular meeting exchange view multicellular organism year ago information boehringer ingelheim microrna ensure example cell meet example joint symposium divide uncontrolle manner hold year year topic different cell type body develop microrna medical application say luisa fertilise egg proudly possible worms fluorescent sensory neuron help understand detail luisa exchange drug developer come bright new gene switch individual microrna idea wait worm change isolate microrna research scientist follow boehringer nose ingelheim drive innovation cancer drug market usa autumn afatinib oncology boehringer ingelheim luisa cochella colleague involve worm identify cell cancer drug boehringer ingelheim research centre vienna groundbreaking work scientist act molecular biologist involve boehringer ingelheim place specialist carry research new research institute molecular pathology imp microrna research course luisa market market cancer drug close collaboration vienna carry research determine wants prepare comprehensive brand gilotrif industrial partner scientist imp aca happen molecular level cell model microrna process round target treatment lung demic institution worldwide acquire wealth divide cancerous tumour develop worm cancer medication regi unique expertise field small molecule bio role microrna play development tere european union therapeutic compound volasertib develop organism imp largely sponsor potential use oncology launch country boehringer ingelheim currently undergo clinical trial boehringer ingelheim carry basic work eventually help development example germany base research work cell division carry research completely independent basis new type medicine microrna giotrif addition imp future acute myeloid leukaemia diabetes oncology oncology biomarker example second new therapeutic area buenos aire vienna detect tumour include medicine boehringer ingelheim luisa typical representative lead inhibit growth tumour internationally renowned research institute important cell differentiation bear buenos aire argentina study possibly cultivate tissue trans usa dutch partner plantation vision far luisa molecular biologist move vienna grateful boehringer ingelheim year head fivemember international imp sponsor farsightedness team research scientist undertake basic research place investment rd basic research characterise truly innovative company boehringer ingelheim continue invest international repute imp conduct research work say biologist research research work boehringer ingelheim microrna roundworm c elegans scien carry collaboration external sponsor highly repute research tist discover short ribonucleic acid mole ensure information partner develop innovative drug institute molecular pathology imp cules microrna consist practical use lose imp research scientist administration method com vienna austria nucleotides present virtually hold regular meeting exchange view pany spend cent total sale scientist carry independent multicellular organism year ago information boehringer ingelheim rd therapeutic area research result microrna ensure example cell meet example joint symposium amount billion euro approximately patent result divide uncontrolled manner hold year year topic imp work repeatedly different cell type body develop microrna medical application say luisa basis research new medicine independent fertilise egg proudly possible boehringer ingelheim foundation addi worm fluorescent sensory neuron help tionally set institute molecular understand detail luisa exchange drug developer come bright new biology imb mainz germany gene switch individual microrna idea foundation finance scientific wait worm change billion euro work carry period isolate microrna year donation mil lion eurosname audrey walsh occupation pensioner voluntary secretary illawarra cancer carer year birth location wollongong australia caring mean b eing involve assist life journey well comfort care able impart fight fit audrey walsh occupation pensioner voluntary secretary illawarra cancer carer year birth live c r e location wollongong australia caring mean b eing involve boehringer ingelheim strive day help patient globe assist life journey audrey walsh tiso awcohmieavne tf haicsti ognoa tlh teh reet icroedm panyc diaenvse tloo ipnsc liundne opvraatdiavxea roung tsh feo prh dairsmeaacseeust iwcailt h well tertiary educator work tirelessly volunteer benefit scheme pbs provide australians high unmet therapeutic need boehringer ingelheim involve comfort care care cancer patient home town affordable access wide range innova traditional therapeutic area scope research develop able impart wollongong kilometre south sydney tive medicine not accept fact secretarmy oefn ll pawroajrerac tcsa insc earl scoa reenrste ar lioncga ln ewa ndtiisceoaagsuel aanretsa wsere include pbs list charity organisation organise funding pradaxa say audrey charge volunteer member consideration course ship addition work week pradaxa case power oncology ward hospital wollongong ful medicine lead undesired effect example massage patient feet chat make tea visitor cope atrial fibrillation audrey effort intend unexpected diagnosis atrial fibrillation cope atrial fibrillation australian dedicated life care life hardly change atrial fibril occasionally need help lation diagnosis s precisely s case sunday fantastic say mean september audrey arrive not clinic checkup visit daughter north queensland time organise day suddenly feel unwell rush emergency department town ville hospital cardiologist examine audrey walsh active continue audrey diagnose atrial fibrillation work illawarra cancer carer meet friend easily lead formation blood visit art exhibition sydney walk clot subsequently result stroke time week travel world cardiologist prescribe audrey anticoagulant spend time family recently pradaxa boehringer ingelheim travel turkey visit berlin travel rhine go london soon return home canada plan new zealand soon raring write letter pradaxa thank support prime minister minister health pbs list local member parliament urge politi fight fit audrey walsh woman action retire cian include pradaxa pharmaceutical tertiary educator work tirelessly volunteer benefit scheme pbs provide australian care cancer patient home town affordable access wide range innova wollongong kilometre south sydney tive medicine not accept fact secretary illawarra cancer carer local anticoagulant include pbs list charity organisation organise funding pradaxa say audrey charge volunteer member consideration course ship addition work week pradaxa case power oncology ward hospital wollongong ful medicine lead undesired effect example massage patient feet chat make tea visitor cope atrial fibrillation audrey effort intend unexpected diagnosis atrial fibrillation cope atrial fibrillation australian dedicated life care life hardly change atrial fibril occasionally need help lation diagnosis s precisely s case sunday fantastic say mean september audrey arrive not clinic checkup visit daughter north queensland time organise day suddenly feel unwell rush emergency department town ville hospital cardiologist examine audrey walsh active continue audrey diagnose atrial fibrillation work illawarra cancer carer meet friend easily lead formation blood visit art exhibition sydney walk clot subsequently result stroke time week travel world cardiologist prescribe audrey anticoagulant spend time family recently pradaxa boehringer ingelheim travel turkey visit berlin travel rhine go london soon return home canada plan new zealand soon raring write letter pradaxa thank support prime minister minister health pbs list local member parliament urge politifighte fit boehringer ingelheim patient experience care health micardis micardis medicine treat high blood pressure market year successful doctor accumulate total mil lion year experience patient successful product approve use country worldwide currently market country micardi million year family include micardisplus twynsta combination product audrey walsh woman action retire cian include pradaxa pharmaceutical tertiary educator work tirelessly volunteer benefit scheme pbs provide australian care cancer patient home town affordable access wide range innova wollongong kilometre south sydney tive medicine not accept fact secretary illawarra cancer carer local anticoagulant include pbs list charity organisation organise funding pradaxa say audrey european approval charge volunteer member consideration course regular health check over striverdi respimat ship addition work week pradaxa case power boehringer ingelheim take care employee health uk denmark iceland oncology ward hospital wollongong ful medicine lead undesired effect german preventive health programme fit life fit european country example massage patient feet job company employee germany receive approval medicine chat make tea visitor cope atrial fibrillation regular multistage health check aim purpose pre striverdi respimat new audrey effort intend vention programme identify individual risk factor early medicine approve unexpected diagnosis atrial fibrillation cope atrial fibrillation stage employee find deal country date largescale australian dedicated life care life hardly change atrial fibril service corporate health management sys clinical trial programme involve occasionally need help lation diagnosis s precisely s tem company receive national corporate patient boehringer case sunday fantastic say mean health award time ingelheim demonstrate effectiveness medicine september audrey arrive not clinic checkup treat chronic obstructive visit daughter north queensland time organise day pulmonary disease copd suddenly feel unwell year rush emergency department town ville hospital cardiologist examine audrey walsh active continue audrey diagnose atrial fibrillation work illawarra cancer carer meet friend easily lead formation blood visit art exhibition sydney walk clot subsequently result stroke time week travel world cardiologist prescribe audrey anticoagulant spend time family recently pradaxa boehringer ingelheim travel turkey visit berlin travel rhine go london soon return home canada plan new zealand soon raring write letter pradaxa thank support product prime minister minister health pbs list boehringer ingelheim successful pre local member parliament urge politi scription drug spiriva treatment copd billion euro angiotensin receptor blocker micardis treatment high blood pressure anticoagulant pradaxa generate net sale billion eurosanythe smile daniele de cilli office little reason laugh boehringer ingelheim boehringer ingelheim subsidiary milan give support need month superior support maine fully employ boehringer ingelheim boehringer ingelheim continue receive salary say convince actively involve social time ve opportunity enterprise enriche live employee dedicate completely different enhance professional skill daniele add head sale training spend month work ing dynamo academy social enterprise involvement charity work way dynamo camp large restrict break work dynamo academy charity organisation italy year spend free time hospital clown put costume recreation therapy camp heart tus wig perform silly trick seriously ill cany child chronic illness child daniele use holiday enter oneweek holiday tain child little happiness daniele de cilli parent free charge away sadness little say occupation training manager daytoday life bring daniele reward hundredfold great boehringer ingelheim memorie beautiful holiday idea normal life possible say daniele dedicate make health year birth foremost manager run location milan italy dynamo academy generate money camp make health project italy able ensure camp initiative launch boehringer ingelheim responsibility mean run increasingly sustainable manner nonprofit organisation ashoka make c hallenge paradigm money necessary thing health support work social entre profit social need generate dynamo academy training preneurs healthcare field worldwide coexist centre annex camp offer corporate team activity example daniele job daniele invest quarter work revamp academys exist range seminar boehringer ingelheim project boehringer ingelheim company actively daniele de cilli enthusiastic time support social responsibility say spend academy camp expe know pre rience joy happiness zest scribe corporate culture life young people sight smile live r e p n b l take responsibility firmly anchor boehringer ingelheim corporate culture company year maintain commitment employee neighbours society environment base boehringer ingelheim corporate value respect trust empathy daniele de cilli office little reason laugh boehringer ingelheim boehringer ingaenldhe pimas ssuibosnidiary milan give support need month superior support maine fully employ boehringer ingelheim boehringer ingelheim continue receive salary say convince actively involve social time ve opportunity enterprise enriche live employee dedicate completely different enhance professional skill daniele add head sale training spend month work ing dynamo academy social enterprise involvement charity work way dynamo camp large restrict break work dynamo academy charity organisation italy year spend free time hospital clown put costume recreation therapy camp heart tus wig perform silly trick seriously ill cany child chronic illness child daniele use holiday enter oneweek holiday tain child little happiness daniele de cilli parent free charge away sadness little say occupation training manager daytoday life bring daniele reward hundredfold great boehringer ingelheim memorie beautiful holiday idea normal life possible say daniele dedicate make health year birth foremost manager run location milan italy dynamo academy generate money camp make health project italy able ensure camp initiative launch boehringer ingelheim responsibility mean run increasingly sustainable manner nonprofit organisation ashoka make c hallenge paradigm money necessary thing health support work social entre profit social need generate dynamo academy training preneurs healthcare field worldwide coexist centre annex camp offer corporate team activity example daniele job daniele invest quarter work revamp academys exist range seminar boehringer ingelheim project boehringer ingelheim company actively daniele de cilli enthusiastic time support social responsibility say spend academy camp expe know pre rience joy happiness zest scribe corporate culture life young people sight smile daniele de cilli office little reason laugh boehringer ingelheim boehringer ingelheim subsidiary milan give support need month superior support maine fully employ boehringer ingelheim boehringer ingelheim continue receive salary say convince actively involve social time ve opportunity enterprise enriche live employee dedicate completely different enhance professional skill daniele add head sale training spend month work ing dynamo academy social enterprise involvement charity work way dynamo camp large restrict break work dynamo academy charity organisation italy year spend free time hospital clown put costume recreation therapy camp heart tus wig perform silly trick seriously ill cany child chronic illness child daniele use holiday enter oneweek holiday tain child little happiness parent free charge away sadness little say daytoday life bring daniele reward hundredfold great memory beautiful holiday idea normal life possible say daniele dedicate make health foremost manager run dynamo academy generate money camp make health project italy able ensure camp initiative launch boehringer ingelheim run increasingly sustainable manner nonprofit organisation ashoka make money necessary thing health support work social entre generate dynamo academy training preneurs healthcare field worldwide centre annexed camp offer corporate team activity example daniele job daniele invest quarter work revamp academys exist range seminar boehringer ingelheim project boehringer ingelheim company actively daniele de cilli enthusiastic time support social responsibility say spend academy camp expe know pre rience joy happiness zest scribe corporate culture life young people sight haveanything boehringer ingelheim smile live responsibility daniele de cilli office little reason laugh boehringer ingelheim boehringer ingelheim subsidiary milan give support need youth venture month superior support maine fully employ boehringer ingelheim programme boehringer ingelheim continue receive salary say social entrepreneur make health launch convince actively involve social time ve opportunity year charity organisation ashoka youth venture programme enterprise enriche live employee dedicate completely different support work socalle social entrepreneur design adolescent enhance professional skill daniele add worldwide business model aim contribute young adult age head sale training spend month work positive change society service provide social chance change ing dynamo academy social enterprise involvement charity work way entrepreneur include scholarship advice entrepreneurial life well dynamo camp large restrict break work dynamo academy issue global network expert develop implement charity organisation italy year spend free concrete idea focus field time hospital clown put costume range nutrition sport workplace environ recreation therapy camp heart tus wig perform silly trick seriously ill mental protection social action cany child chronic illness child daniele use holiday enter trainee boehringer ingelheim oneweek holiday tain child little happiness employee child drive parent free charge away sadness little say boehringer ingelheim force project daytoday life bring daniele reward hundredfold great make health initiative memorie beautiful holiday boehringer ingelheim celebrate idea normal life possible say daniele dedicate make health th anniversary company foremost manager run occasion launch make health dynamo academy generate money camp make health project italy initiative run today country aim improve able ensure camp initiative launch boehringer ingelheim health society end make run increasingly sustainable manner nonprofit organisation ashoka make health support social entrepreneur money necessary thing health support work social entre field healthcare order identify new generate dynamo academy training preneur healthcare field worldwide approach push ahead develop centre annexed camp offer corporate team ment close collaboration ashoka activity example daniele job daniele invest quarter work fundamental achieving aim revamp academys exist range seminar boehringer ingelheim project year boehringer ingelheim company actively daniele de cilli enthusiastic time support social responsibility say spend academy camp expe know pre rience joy happiness zest scribe corporate culture life young people sight havename albert boehringer occupation founder company year birth location ingelheim germany independence mean albert boehringer successful grow one effort achieve goal focus early stage research employee satisfaction sense family serve humankind living n e p e n e n c e independent familyowne business key focus boehringer ingelheim longterm sustainable action achieve goal require sound wear plain suit traditional loden example buy car second finance organic corporate growth boehringer ingelheim corporate jacket stand thoughtfully entrance hand shortage coal culture base value apply company c h boehringer sohn chbs watch production risk simply acquire lorry leavingf tohuen fadcetodr yin supply customer disuse colliery employee company late product cardio give priority world war vascular drug sympatol modestlooking example continue pay salary man factory gate enlist army intro yearold councillor commerce albert duce health insurance scheme company boehringer company founder owner employee early offer pay leave com lose thought pause moment con pany pension scheme inexpensive housing sider long journey factory worker lot bene fit far common day chbs parent company today boehringer ingelheim difficult time key principle albert boehringer recognise hyperinflation germany importance good people work french occupation rhineland like nephew robert boehringer world war follow launch run company world war respiratory product lobelin succeed heinrich wieland cousin albert boehringer make highly effective drug sympatol wife helene later receive nobel available patient success drug prize chemistry important albert secure financial independence family boehringer know company own company run member family early stage son soninlaw join son family entrepreneur mann company today boehringer von baumbach heim southwest germany start business family fourth generation continue simple circumstance pro manage company fortune producer duction chemical compound tartaric tartaric acid nieder ingelheim develop lactic acid year later today inter nationally successful pharma clear albert boehringer inherit ceutical company albert boehringer right combination business talent young envision development watch entrepreneur invest money tradi lorry leave factory laden sympatol tional virtue thrift native swabia specific area thoughtserving boehringer humankind ingelheim maintain hubertus von baumbach member board manage independence director responsibility finance year christian boehringer appoint chairman shareholder committee wear plain suit traditional loden example buy car second jacket stand thoughtfully entrance hand shortage coal c h boehringer sohn chbs watch production risk simply acquire owner family withdraw follow death lorry leave factory supply customer disuse colliery employee management death albert ernst hubertus liebrecht oversees boehringer julius company late product cardio give priority world war company julius liebrecht son liebrecht appoint vascular drug sympatol modestlooking example continue pay salaries shareholders committee hubertus appoint chairman board chairmanship take chairman board director man factory gate enlist army intro erich h von baumbach director yearold councillor commerce albert duce health insurance scheme company company go boehringer company founder owner employee early offer pay leave com international lose thought pause moment con pany pension scheme inexpensive housing sider long journey factory worker lot bene fit far common day albert boehringer pur chbs parent company today boehringer chases tartar factory albert brother ernst niederingelheim lay ingelheim difficult time key principle albert boehringer recognise boehringer join foundation albert boehringer julius liebrecht mar board directors hyperinflation germany importance good people work presentday company jr son com rie ilse daughter pany founder company founder join french occupation rhineland like nephew robert boehringer join board board director world war follow launch run company world war director respiratory product lobelin succeed heinrich wieland cousin albert boehringer make highly effective drug sympatol wife helene later receive nobel available patient success drug prize chemistry important albert independence fundamental independent boehringer independence unique independence stand secured financial independence family boehringer know company protect business ingelheim enable focus opportunity bold family commitment sus value key guarantee generate longterm professionally personally taine profitability create own company run member family early stage e integrity decision make sustainable healthcare solu company provide value base innovation son soninlaw join safeguard patient safety tion customer autonomy develop enable establish innov son family entrepreneur mann company today boehringer von baumbach reduce need react fre powerful brand way ative technology accord sophie fontez regional heim southwest germany start business family fourth generation continue quently external market boehringer ingelheim ance company guid pharmacovigilance head simple circumstance pro manage company fortune producer asia middle eastnorth fluctuation ing principle leitbild africa renato camera duction chemical compound tartaric tartaric acid nieder ingelheim develop arthur mendonca senior brand manager dr silke ldtke boehringer ingelheim regional business manager head bioanalysis lactic acid year later today inter nationally successful pharma brasil emerge market area biomarker development clear albert boehringer inherit ceutical company albert boehringer management germany right combination business talent young envision development watch entrepreneur invest money tradi lorry leave factory laden sympatol tional virtue thrift native swabia specific area thoughtserving boehringer humankind ingelheim maintain hubertus von baumbach member board manage independence director responsibility finance year christian boehringer appoint chairman shareholder committee wear plain suit traditional loden example buy car second jacket stand thoughtfully entrance hand shortage coal c h boehringer sohn chbs watch production risk simply acquire owner family withdraw follow death lorry leave factory supply customer disuse colliery employee management death albert ernst hubertus liebrecht oversees boehringer julius company late product cardio give priority world war company julius liebrecht son liebrecht appoint vascular drug sympatol modestlooking example continue pay salaries shareholders committee hubertus appoint chairman board chairmanship take chairman board director man factory gate enlist army intro erich h von baumbach director yearold councillor commerce albert duce health insurance scheme company company go boehringer company founder owner employee early offer pay leave com international lose thought pause moment con pany pension scheme inexpensive housing sider long journey factory worker lot bene fit far common day albert boehringer pur chbs parent company today boehringer chases tartar factory albert brother ernst niederingelheim lay ingelheim difficult time key principle albert boehringer recognise boehringer join foundation albert boehringer julius liebrecht mar board directors hyperinflation germany importance good people work presentday company jr son com rie ilse daughter pany founder company founder join french occupation rhineland like nephew robert boehringer join board board director world war follow launch run company world war director respiratory product lobelin succeed heinrich wieland cousin albert boehringer make highly effective drug sympatol wife helene later receive nobel available patient success drug prize chemistry important albert independence fundamental independent boehringer independence unique independence stand secured financial independence family boehringer know company protect business ingelheim enable focus opportunity bold family commitment sus value key guarantee generate longterm professionally personally taine profitability create own company run member family early stage e integrity decision make sustainable healthcare solu company provide value base innovation son soninlaw join safeguard patient safety tion customer autonomy develop enable establish innov son family entrepreneur mann company today boehringer von baumbach reduce need react fre powerful brand way ative technology accord sophie fontez regional heim southwest germany start business family fourth generation continue quently external market boehringer ingelheim ance company guid pharmacovigilance head simple circumstance pro manage company fortune producer asia middle eastnorth fluctuation ing principle leitbild africa renato camera duction chemical compound tartaric tartaric acid nieder ingelheim develop arthur mendonca senior brand manager dr silke ldtke boehringer ingelheim regional business manager head bioanalysis lactic acid year later today inter nationally successful pharma brasil emerge market area biomarker development clear albert boehringer inherit ceutical company albert boehringer management germany right combination business talent young envision development watch entrepreneur invest money tradi lorry leave factory laden sympatol tional virtue thrift native swabia specific area thoughtgroup management report boehringer ingelheim annual report group management report group management report information group company report economic position report postbalance sheet date event risk report report expect development information group company group management report information group company group business model boehringer ingelheim researchdriven group com buscopan dulcolax pharmaton boehringer panie dedicate research development pro ingelheim large supplier veterinary duction marketing pharmaceutical high drug worldwide business ingelvac circoflex therapeutic value human medicine animal currently topselle brand health boehringer ingelheim group consist company employ people field growth company development net sale amount eur billion boehringer production biopharmaceutical business ingelheim pharmaceutical company focus contract manufacturing biosimilar worldwide boehringer ingelheim activity consist addition research development new biological follow business prescription medicine con sumer health care animal health bio pharmaceutical industrial customer net sale business million eur prescription medicine business continue prescription medicine mainstay company business medicinal product boehringer ingelheim establish standard treatment disease respiratory tract cardiovascular system central nervous sys consumer health care tem addition metabolic disorder infectious disease important medicinal product supply boehringer ingelheim include spiriva treat ment chronic obstructive pulmonary disease copd animal health micardis treatment hypertension drug pradaxa prevention stroke patient suffer atrial fibrillation thromboembolic disorder trajenta treatment type dia biopharmaceutical bete report continuous growth launch support boehringer ingelheim positive business performance industrial customer sale company bestselle product consumer health care business include drug mucosolvan boehringer ingelheim annual report group management report net sale region millions eur research development rd line boehringer ingelheim mission statement primary goal develop innovative drug thera pie treatment disease satisfactory treatment available aim time major contribution europe area need treatment high occupy lead position major indication area asia australia africa order achieve goal ensure important america aaa technology remain state art systematically examine new technological approach regular contact global network academic group public research institutes biotech company provide boehringer drug boehringer ingelheim europe lead ingelheim access late development provider contract manufacturing biotechnically finding addition regularly supplement prod manufacture pharmaceutical product devel uct portfolio specific inlicense joint ven ope manufacture facility biberach ger ture agreement vienna austria fremont usa cell cul ture microorganism employ average people rd ite majority boehringer ingelheim sale achieve americas europe total eur billion invest worldwide group net sale generate research development new drugs usa japan germany net sale e ur equivalent group net sale billion asiaaustraliaafrica aaa region level prior year account group net sale grow importance addition establish financial year addition giotrif region primarily emerge market russia nonsmall cell lung cancer pradaxa treat brazil india china africa particular ment prevention deep vein thrombosis pulmo grow significance individual emerge market nary embolism launch number specific boehringer ingelheim achieve growth rate market striverdi olodaterol respimat chronic excess obstructive pulmonary disease copd receive regulato ry approval way company continue boehringer ingelheim focus research de renew expand product portfolio velopment rd innovative medicine therapie ultimate goal secure future growth phar maceutical business product company research evelopment boehringer ingelheim operate global research network large site germany biberach usa ridgefield austria vienna information group company research development expenditure eur million net sale prescription medicine expenditure eur million prescription medicine net sale average number employee investment tangible asset investment infrastructure eur million human pharmaceutical chronic obstructive pulmonary disease copd boehringer ingelheim carry research develop volved patient particular study ment business prescription medicine show comparable time exacerbation copd consumer health care facilities usa ger comparable tolerance spiriva tiotropium austria italy japan formulation respimat handihaler study demonstrate use spiriva respimat key focus research work spiriva handihaler similar impact surviv follow indication area al important survival advantage show previous uplift trial treatment respiratory disease spiriva handihaler compare cardiometabolic disorder cardiovascular control treatment result basis submit etabolic disorder ting marketing authorisation application spiriva oncology respimat usa respimat inhaler propel disease central nervous system lantfree soft mist inhaler stand immunology ard application device future respiratory product infectious disease olodaterol respimat addition expenditure rd prescription medicine account current treatment phase iii trial involve copd ed net sale generate business patient show statistically significant improvement lung function olodaterol highly selective longacte key study datum financial year pre beta agonist laba boehringer ingelheim research sente pipeline olodaterol approve use brand striverdi respimat time boehringer ingelheim world lead phar maceutical company treatment respiratory new datum tiotropium asthma demonstrate disease addition successful product date tiotropium respimat effective treatment research tiotropium availa symptomatic asthma patient regardless allergy ble year brand spiriva status age smoke behaviour bronchodilator reac company comprehensive research develop tion tiotropium give daily respimat signifi ment pipeline cantly improve lung function tiotropium safety performance respimat asthma patient remain symptomatic despite tiospir large trial conduct treatment inhale corticosteroid ic long boehringer ingelheim annual report group management report act beta agonist laba focus repli demonstrate specific highly selective antibody cate doubleblind parallel group trial tiotropium fragment fab potential duced asthma exacerbation patient remain need prove clinical study symptomatic despite treatment icslaba medicine regardless exhibit allergic indication area metabolic disorder focus symptom research development drug treatment diabetes patient remain symptomatic despite treatment ics achieve statistically significant clini key trial linagliptin carmelina de cally relevant improvement asthma control mean sign investigate effect linagliptin compare oncedaily dose tiotropium confirm standard treatment term cardiovascu datum mezzotinaasthma phase iii twin study lar renal microvascular event current approval procedure use tiotropium asth c arolina trial eventdriven cardio initiate european union eu sec vascular endpoint trial directly compare dpp ond half inhibitor linagliptin sulfonylurea glimepiride addition respiratory disease field cardio end half suc metabolic disorder important research field cessfully complete number key trial inve boehringer ingelheim thing expand tigational compound empagliflozin phase iii clinical development programme pradaxa dab empar eg clinical trial programme programme igatran etexilate field focus type diabete involve patient include multinational clinical trial remedy resonate recover clinical recruitment complete empareg trial demonstrate pradaxa effective outcome eventdriven cardiovascular endpoint time exhibit favourable safety profile trial design assess effect empagliflozin com treatment acute deep vein thrombosis pulmonary pare standard treatment involve people embolism subsequent secondary prevention type diabete high cardiovascular risk end boehringer ingelheim announce indication area oncology boehringer ingelheim new phase iii trial plan respect involve research development new type esus carry research determine efficacy cancer treatment offer patient add thera safety pradaxa prevent stroke peutic value contribute improvement patient stroke embolic origin quality life unknown source redual pci address question efficacy safety pradaxa pre data luxlung phase iii trial vent blood clot patient atrial fibrillation patient receive giotrif afatinib receive stent result narrow blood alive year later show tumour progression vessel supply blood heart case patient treat chemotherapy new result con improve patient safety boehringer ingelheim firm finding company previous luxlung working antidote reverse anticoagula phase iii trial demonstrate giotrif superi tion effect pradaxa initial result study standard chemotherapy patient egfr healthy volunteer phase clinical trial erbb mutationpositive nonsmall cell lung cancer information group company nsclc addition possible demonstrate animal health treatment giotrif patient type boehringer ingelheim research animal health lung cancer lead significant delay tumour business focus research development progression improve quality life novative vaccine primarily protect livestock com authority eu large number panion animal addition pharmaceutical product country europe americas asia ap company invest eur million prove giotrif drug approve research development new product set usa brand gilotrif te new rd facility equivalent net sale generate company animal health nintedanib treatment lung cancer business combination chemotherapy extend life patient initial treatment fail facilities usa germany mexico china year show result lume japan denmark india netherlands focus lung phase iii clinical trial basis research new drug development future sult boehringer ingelheim submit application therapeutic solution vaccine base european medicine agency ema author local pathogen pathogen variant imperative itie second half approval present key sale region nintedanib research development production facility startverso phase iii programme demonstrate european research centre animal vaccine faldaprevir combination pegylate interferon hanover begin operation financial year ribavirin prove effective safe large num company invest eur million ber hepatitis patient infect genotype includ boehringer ingelheim veterinary research centre e patient advance liver disease pa bivrc tient receive previous treatment early treatment success short duration china activity asian research de treatment achieve company submit applica velopment centre veterinary medicine ex tion food drug administration fda pande end boehringer ingelheim al ema authority worldwide ap ready invest total eur million investment proval faldaprevir demonstrate company commitment intention strengthen position animal health consumer health care business boehringer ingel heim successfully launch product boxagrippal financial year boehringer ingelheim receive vaprino german market substance european market authorisation new drug available overthecounter medication veterinary medicine pexion treatment epilep obtain prescription boxagrippal contain sy dogs semintra treatment chronic kidney combination ibuprofen pseudeoephedrin disease cat prozinc insulin treatment consumer health care market vaprino secre type diabete mellitus cats usa new vaccine tion blocker therapy acut diarrohea adult approve cat prevent rabie vaccine year age prevention influenza dog vaccine prevention salmonellosis typhimurium swine vaccine cattle europe bovela bvd submit ema clinical programme boehringer ingelheim annual report group management report new vaccine porcine reproductive respiratory syn challenge term technology pro drome prrs europe complete cesse involve production guidance party management human pharmaceutical pm department network contract management global production network consist organisation cmos focus manufacture facility country spread production product establish market site group operate pharmaceutical chemical advanced stage life cycle ensure relia biopharmaceutical production unit pro ble competitive supply prescription medicine duction unit medicinal device high priority consumer health care product accordance site provide reliable highquality sup relevant requirement ply product customer group external industrial client local presence growth market production pm network enable provide high october boehringer ingelheim announce level flexibility position respond optimal closing production subsidiary ben ly local need venue laboratory inc bedford ohio end despite close collaboration fda ut september boehringer ingelheim inaugurate ex commitment workforce investment tension production facility building design improve facility possible secure lev accommodate chemical research development el sustainable production require particularly laboratory zhangjiang hitech park shanghai market environment change significantly china total investment cost eur million site zhangjiang boehringer ingel follow inspection manufacturing process heim important centre asiapacific region production site ingelheim food size workforce increase drug administration issue warning letter aim triple production capacity extend result concern relate compliance ing site possible add new competence current good manufacturing practice cgmp expand capacity set effective supply chain boehringer ingelheim take matter seriously project include packaging centre result warning letter comprehensive initia space accommodate late packaging system new tive launch response fdas con quality control laboratory automatic warehous cern action plan file fda cur ing logistics area reliable highquality delivery rently implement fully comply cgmp market launch new medicinal product standard important technology solid form tablet liquid syrup anticipate production capacity chemical pharmaceutical production facility million package increase mil product launch group pharma lion ceutical chemical manufacture pcm division act interface development new building erect centre activity series production division responsi competence move waigaoqiao ble compliance high quality standard zhangjiang focus work carry rd organise new product launch production chemical laboratory operation innovative product entire life cycle process optimisation performance information group company analytical test pharmaceutical chemical inter company shanghai china build cgmp bioparma mediate purchase boehringer ingelheim ceutical facility new site provide variety strategic partner china clinical development service chinese multi national customer facility equip biopharmaceutical ment require process development production addition manufacture proprietary actilyse accordance cgmp schedule completion metalyse imukin beromun development early boehringer ingelheim planning invest product boehringer ingelheim biopharmaceutical pro eur million create job duction facility fremont usa biberach germany vienna austria globally recognise contract boehringer ingelheim year strategic alliance manufacturer thirdparty client company cov pharmaceutical company rochegenentech er entire biopharmaceutical process chain ge celebrate october joint development work netic development cell follow manufacture carry company result successful filling finish pharmaceutical product product actilyse metalyse imukin product launch global market supply beromun help patient worldwide year collaboration contract manufacture largescale cell culture facility packing facility addition development product include biberach successful process validation production brand product activase pradaxa antidote complete applica boehringer ingelheim american market roche tion approval molecule plan genentech animal health financial year boehringer ingelheim success partnership taizhou china medical city fully conclude new contract contract manufactur boehringer ingelheim announce august construc ing business include production agreement peri tion production facility veterinary vaccine od year lead swiss pharmaceutical province jiangsu china joint venture include company recombinant protein successful total investment eur million completion spection fda production site vienna fda production facility employ worker approval new isolator line biberach site schedule june help joint venture give asceptic production biopharmaceutical develop leading force chinese animal hus boehringer ingelheim negotiate development bandry sector future facility produce vaccine production agreement pharmaceutical com primarily treatment swine poultry disease panie molecule produce cell cul china asian market investment ture production facility biberach fremont line longterm commitment china swedish company sobi boehringer ingel heim receive fda european ema ap environmental employee protection proval production facility vienna pro concern social ecological issue firmly duction brand product kineret inhibits anchor boehringer ingelheim corporate philosophy biological activity interleukin major year crucial importance compa impact inflammatory disorder nys longterm development high value place issue reflect mission statement boehringer ingelheim sign cooperation agreement protection employee facility zhangjiang biotech pharmaceutical base environment addition sustainable pru boehringer ingelheim annual report group management report dent use natural resource promotion envi expertise company facility co ronmental awareness key component ordinating project international level observe social ecological concern way co emission index calculate ensure enjoy sustainable business success annual basis indicate trend right direc boehringer ingelheim demonstrate commitment tion ultimately enable achieve ambi responsibility participate responsible care tious target initiative world chemical association priority boehringer ingelheim give health bind standard environmental protection health safety employee reflect high occupational safety long implement global safety standard guideline group company internal guide implementation safety culture groupwide line reflect respective countryspecific legal require initiative safe launch aim ment significantly exceed case reduce number work accident roll large number international division environment health safety eh facility effort design achieve goal sponsible introducing review internal envi plan mena middle east north africa ronmental occupational safety guideline compli region example small facility latin ance standard status environmental america employee protection examine regular audits order continuously identify potential area initiative member senior management improvement total internal ehs audits entire workforce play key role proactively tak form group financial year ing responsibility safety safety colleague accident rate accident example continuous improvement environ million hour work remain sim mental protection iso certification suc ilar level prior year cessfully begin ingelheim site ingelheim active ingredient drug produce employee report year company launch comprehensive previous year boehringer ingelheim workforce examination decontamination ground increase financial year average number adjacent plant premise continue people employ boehringer ingelheim year technical progress improve information mean equivalent increase com problem nature analyse pare prior year accurately previously case expert field geochemistry environmental toxicology en average number employee region gineering consult advice implement america measure europe asiaaustraliaafrica aaa boehringer ingelheim set ambitious target cut co emission achieve include potential energy saving result increase workforce new admin reduction emission promote exchange istration build erect headquarters information group company ingelheim boehringer ingelheim invest eur mil company performance individual target lion new building accommodate em achieve individual employee con ployee build schedule completion tinuous communication process employee end superior individual target agree cur rent year beginning year achievement boehringer ingelheim employee important fac target ultimately direct effect variable tor successful future development company salary component extensive voluntary social benefit accordingly particularly commit actively de company pension scheme preventive health veloping support employee ensure examination round attractive salary system ideally equip deal challenge ahead opinion place good competitive position comprehensive training system place great importance acquisition technical skill member senior management boehringer ingelheim promotion social skill receive salary component link company longterm success variable salary component apprenticeship vital source qualified young people gear attainment longterm company traditionally boehringer ingelheim special target concern purpose graduate choose different career path company german facili build commitment innovation vi tie germany boehringer ingelheim invest tality workforce regard good balance eur million year career training tween career private life key corpo addition specific skill apprentice encourage rate success satisfaction workplace effort act independently creative responsibil support member workforce ity financial year employ appren clude provision service bifit fitness tices germany programme medical care comprehensive advice sup port family provide child care parttime work integral corporate strategy talent man flexible working hour service kind base agement particularly important aim pro local requirement individual country gramme right people right place right time enable employability career november boehringer ingelheim receive development employee development poten corporate health award time emphasise tial identify specially prepare strategically high value corporate health management enjoy important position early stage behaviour boehringer ingelheim future boehringer ingel performance deliver employee assess heim aim continuously expand corporate health purpose appropriate distinction management service new area term salary career development opportunity involve healthy leadership addition strong corporate culture approach enable recruit highly qualified employee corporate citizenship competitive business environment ensure decade boehringer ingelheim actively remain loyal boehringer ingelheim long term volve area extend far business interest social responsibility commitment soci salary system boehringer ingelheim include ety cover wide range issue boehringer competitive basic salary variable salary component ingelheim firmly anchor corporate phi variable component base losophy future commitment boehringer ingelheim annual report group management report wellbee patient employee family th autumn run ingelheim provide opportu focus initiative support par nity employee involve ticipation project design help event dedicated good cause company needy activity actively encourage particular donate sum money social project partic ly country region business ipant sporting event example boehringer ingelheim social commit online webbase changemaker competition ment implementation un convention launch competition encourage mem right person disability action plan ber general public send new idea way specify goal idea enable m healthcare improve poorly support plement un convention area organisa environment addition example make tion bring change workplace health partnership include variety addi design barrierfree access social benefit tional initiative project addition longterm initiative boehringer open differ idea opinion ingelheim provide help urgently need draw great diversity experience cultural example boehringer ingelheim donate background different character personalitie flood victim eastern part germany possible boehringer ingelheim remain true victim devastate typhoon haiyan phil motto value innovation desire create ippine philippine availa work environment open diversity dif ble german red cross emergency aid phil ference fundamental pillar cor ippine subsidiary boehringer ingelheim support porate culture diversity inclusion help live local aid organisation donation cash core value respect trust empathy passion medicine cause value important boehringer ingel heim response corporate charter diversi social commitment employee encourage ty germany company nationwide diversity boehringer ingelheim year day hold june programme partnership set make event focus aspect diversity health initiative boehringer ingelheim ashoka international nonprofit organisation boehringer ingelheim active supporter major social commitment research science culture year longterm aim partnership promote health people partnership academic institution serve world include f amilie social line group systematic focus research develop environment identify implement promising ment addition support sponsor scientific solution deal health problem order activity company present scientist award achieve goal support give select boehringer ingelheim fen research award social entrepreneur worldwide push ahead neuroscience company award effective longterm solution healthcare field heinrich wieland price annually outstanding research end boehringer ingelheim em active biological molecule system ployee participate make health ini clinical relevance tiative country report economic position report economic accord consumer price index aver position age inflation rate germany decelerate reason exist price increase high cost energy food entire macroeconomic environment eurozone annual inflation rate follow euro crisis global economy stabilise compare previous year growth rate level previous year result previous financial year performance expansionary monetary policy upswe dollar usd japanese yen jpy country selfsustaine global key currency boehringer ingelheim vary dustrial production increase moderately drive euro exchange rate dollar show lateral strengthen industrialise nation contrast slow movement range usdeur march rate economic growth emerge usdeur december japanese yen exchange develop country continue foreign trade rate drop significantly euro course country actually decline slightly end start rate january jpyeur year major driver positive trend global rise jpyeur end december economy primarily positive investor sentiment usa economic recovery japan euro growth global pharmaceutical market zone large extent move recession support affect expiry patent prod ed strong german economy continue stabi uct earn billion sale great competition lisation euro country generic product measure take restrict cost government health authority regain slight increase growth rate global economy momentum second half grow expect series early indicator overall performance primar point continue recovery economy m ily primarily contribution emerge provement confidence see case com country case doubledigit growth rate panie consumer industrialise nation acceleration production growth recovery course business housing market see usa low rate focus boehringer ingelheim business activity growth continues expect eurozone weak securing group independence ene growth expect japan fiscal basis achievement longterm policy measure responsible economic upswing sustainable development company accompany expire come year stable profit solid finance economic output germany year mark number challenge face indicator increase consumer spend transition year group result numer ing point continuation upswing signal ous measure take change end weak phase positive result research development activity basis business performance positive emerge trend see today theless lay year come perspective likely continue come year growth expect primarily net sale amount eur million increase consumer spending represent change compare boehringer ingelheim annual report group management report exchange rate development foreign exchange letter offset effect result market associate exchange rate effect measure initiative increase efficiency reduce negative impact currency adjust boehringer ingel cost introduce year group heim growth rate stand mean despite turn net sale increase decline sale product lose exclusivity key figure eur million change country eg micardis sifrol viramune net sale company continue growth trend operating income return net sale sale eur million total sale america region remain company important sale market decline importance result operation region compare previous year result primarily boehringer ingelheim business activity devide change eurusd exchange rate prescription medicine consumer health care associate low sale currency adjust animal health biopharmaceutical industrial cus ed europe boehringer ingelheim generate net sale tomer amount eur million equivalent net sale business currency total sale growth currency eur million change adjust adjust compare previous year prescription medicine global sale amount eur million attrib consumer health care utable asiaaustraliaafrica region share animal health group sale approximately equivalent biopharmaceutical previous year net sale region decline industrial customer sale adjust currency effect increase achieve prescription medicine net sale region currency share overall sale prescription medi eur million change adjust cine key pillar boehringer ingelheim activity america net sale amount eur million europe equivalent change compare asiaaustraliaafrica aaa previous year currency adjust overall satisfied development previous year spiriva treat sale despite difficult year growth chronic obstructive pulmonary disease copd achieve basis establish product best elle product reporting period generate newly launch product adjustment exchange sale eur million level rate effect compare previous year previous year large sale market usa sale promise innovative product pipeline serve af spiriva increase result total firm action company sale eur million boehringer ingelheim generate operating income base sale second important product amount eur million factor affect boehringer ingelheim icardi drug treatment result closure site bedford usa high blood pressure generate sale amount additional expense result fda warn eur million previous report economic position year level decline expect result aaa region achieve net sale eur million ed loss exclusivity market equivalent share region report ed slight decline compare previous launch anticoagulant pradaxa year result large extent currency increase sale eur million prove related decline sale japan currency adjust driver growth growth achieve region japan boehringer ingelheim generate net sale eur mil net sales eur million change lion correspond change compare spiriva previous year micardis pradaxa consumer health care combivent remain difficult market environment sale consumer health care business term regional distribution sale region currency adjust compare previous europe market reporting increase year business boehringer ingelheim generate prescription medicine business region asia sale amount eur million australiaafrica aaa contrast report decline sale compare previous year bestselle product consumer health care business mucosolvan buscopan net sale region dulcolax pharmaton product generate eur million change sale eur million previous america year buscopan net sales eur million europe big seller term growth mucosolvan en asiaaustraliaafrica aaa joy sale increase report sale amount eur million previous year america share far large exceed million mark zantac bisolvon market boehringer ingelheim generate sale amount eur million equivalent change net sale eur million change currency adjust compare buscopan previous year great impact development dulcolax america sale performance m mucosolvan portant market usa sales eur mil pharmaton lion decrease primarily result unfavourable exchange rate development consider region europe generate high net sale eur million correspond europe second large market account share share global net sale consumer health sale amount eur million care business business europe grow growth market region europe achieve currency adjust germany growth currency adjust compare important market boehringer ingelheim business performance europe drive primarily growth generate uk contribute eur million germany large market growth america region second large sale market stagnate total sale amount eur million consumer health care business end financial boehringer ingelheim annual report group management report year slight decline currency ad eur million sale usa large juste compare previous year achieve market remain previous year level canada total net sale eur million correspond brazil report decline business share region total chc business far large market usa remain stable com region europe boehringer ingelheim pare report slight growth financial year currency adjust net sale germany aaa region end financial year net remain stable level previous year france sale amount eur million second large european market perform currency adjust previous positively year market account boehringer ingelheim consumer health care business main biopharmaceutical driver decline japanese market financial year boehringer ingelheim net sale decline currency effect manage biopharmaceutical business separate eur million division consist contract manufacturing biosimilar research development new bio animal health logical active ingredient sale amount sale business animal health product eur million represent decline increase eur million result weak contract manufacturing business currency adjust level pre compare previous year vious year large percentage sale attributable livestock product eur million ac industrial customer sale count livestock segment equivalent industrial customer business encompasse share eur million bestselle prod thirdparty business field pharmaceutical pro uct year swine vaccine ingelvac circoflex duction contract manufacturing business business companion animal segment generate fur pharma chemical net sale amount eur mil ther eur million correspond share lion generate equivalent growth currency adjust net sale eur million change ingelvac circoflex presentation expenditure income metacam financial year boehringer ingelheim operat ingelvac prrs ing expense drop eur million repre duramune sent change compare previous year eur million material cost remain level large contribution growth come previous year eur million represent emerge market aaa region region grow material cost share total sale personnel currency adjust overall eur mil cost amount eur million lion chinese market particular net sale increase slightly level eur million eur million result personnel expense share come share business net sale ameri amortisation drop compare pre cas large region report slight decline vious year amount eur million op currency adjust compare previous year erate expense decline yearonyear eur report economic position report postbalance sheet date event risk report million thing cost block result boehringer ingelheim international orien cludes commission licence payment de tation development foreign exchange rate mar pendent sale reduction operate ex ket considerable impact company finan pense compare previous year particular result cial performance importance business exchange rate effect sustainable ef associate supply relationship mean ex ficiency initiative instigate year operate income change rate development dollar constitute despite situation subsidiary ben venue lab great individual risk framework group oratory inc action take result wide financial report foreign exchange risk calculat fda warning letter level previous ed hedge derivative financial instrument year increase compare nature scope measure set eur million group guideline regularly discuss rele vant committee standardise process report period financial income total eur million eur million compare investment great importance boehringer ingel previous year largely attributable heim future continuous investment requirement interest effect pension commitment company longterm development form ba sis profitable growth business income taxis develop line result operating activity increase total eur million invest tangible eur million intangible asset year review tax expense amount eur million continue meet positive demand respimat take consideration provision soft mist inhaler company move ahead german commercial law shareholder personal taxis expansion production capacity dortmund arise group business activity recog ingelheim site investment amount nised tax expense instead taxis present eur million respimat soft mist inhaler withdrawal group equity take ex manufacture boehringer ingelheim microparts traordinary effect account actual tax ratio gmbh dortmund fill correspond markedly high figure show profit pharmaceutical active ingredient ingelheim site loss statement global distribution important growth market china boehringer ingelheim invest financial year net income boehringer eur million expansion production facili ingelheim group total eur million tie build accommodate chemical rd level previous year eur mil laboratory shanghai china research development lion field human animal medicine main priority boehringer ingelheim future financial position end additional investment rd boehringer ingelheim financial management instru facilities germany austria usa ment method aim secure liquidity limit ing financial economic risk optimise cost cash flow stand eur million con capital suitable capital structure finan stitute decline compare mainly cial activity gear support high level receivables compare previous company business strategy year cash flow operating activity fall eur mil boehringer ingelheim annual report group management report lion eur million despite decrease pre year review despite decrease liability vious year investment finance entirely bank remain stable eur million fund generate company balance sheet respective balance sheet ratio total eur million invest tangible asset round positive picture show finan eur million intangible asset cash flow cial position result operation combine operating activity exceed cash flow investing evaluation net asset financial position result financing activity result increased securi operation show boehringer ingelheim tie liquid fund yearend eur million soundly finance profitable company summary emphasise exist report postbalance liquidity financial structure high cash flow operating activity prerequisite sta sheet date event ble continuation business activity suc cessful implementation strategy fulfil end financial year net asset come aware event material significance financial year boehringer ingelheim total group company lead asset amount eur million increase appraisal net asset financial position result eur million compare previous operation year tangible intangible asset total eur mil lion fully cover consolidated equity risk report end financial year financial asset reach figure eur million eur million risk opportunity management high previous year inventory change aim risk management system implement remain virtually unchanged eur mil boehringer ingelheim identify businessspecific risk lion eur million trade account receivable particular risk jeopardise continue ex rose eur million eur million istence company early possible assess liquid fund include nonfixed security stand reduce reasonable level mean suit eur million eur million able measure abovementione change cash cash assess risk context holistic risk equivalent group equity amount eur mil management endeavour account lion long term addition equity pen result opportunity opportunity management sion provision longterm liability available base company strategy objective addi group item total eur mil tion individual business operate business lion equivalent total asset unit integral groupwide planning consequently longterm disposable capital cover management system responsible busi tangible tangible asset inventory trade account ness function bear direct responsibility ear receivable provision eur million ly systematic identification analysis use op level previous year liability hardly change portunitie boehringer ingelheim researchdriven innovative company current rd activity risk report naturally consider relevant opportunity detailed monitor quantifie risk regular interval description project illustrate rd make predictable future business mean chapter relevant hedging strategy appropriate financial instrument forward exchange contract person responsible key business func sultant risk subsequently designate con tion include process calculate assess crete controllable ing risk groupwide risk information system en sure identify risk analyse assess credit countryspecific risk carefully follow appropriate classification var boehringer ingelheim expose credit ious category adequate countermeasure initiate countryspecific risk result international busi implementation consistently monitor ness activity portfolio trade account ceivable trade account payable identi year review internal auditing perform tar fied extraordinary risk group get routine audit extraordinary audits usual level sector apply possible de world addition adherence legal requirement fault risk receivables largely hedge internal group guideline main focal point economic political risk continue functionality system effectiveness internal carefully track credit countryspecific risk control prevention loss asset effi position respond negative change timely man ciency structure process correspond adjust ner risk regard concrete ment optimisation initiate necessary management financial investment risk individual risk group pursue defensive investment strategy important risk boehringer ingelheim management financial asset reflect expose present separately break orientation portfolio focus european follow specific category financial risk legal economic monetary union emu government bond risk production environmental risk personnel risk credit rating shortterm investment se sectorspecific risk lecte bank result concrete risk risk identify concrete legal risk appear controllable mean specific manage business activity group expose legal ment procedure case risk regardless risk distinction regulatory liability probability occurrence completely patent protection risk control mean target management proce dure term abstract regulatory risk boehringer ingelheim expose risk arise le financial risk gal dispute proceeding official investiga relevant financial risk break tion legal administrative decision ongoing follow currency risk credit countryspecific risk future proceeding predict regard plus management financial investment risk resultant risk abstract currency risk liability risk global orientation business activity result market sale pharmaceutical expose currency risk exchange rate volatility group potential product liability risk boehringer ingelheim boehringer ingelheim annual report group management report currently product liability insurance compa risk area environment health safety nys risk profile absolutely guarantee howev ehs minimise preventively adherence er insurance coverage maintain rea extremely high safety standard appropriate emer sonable cost acceptable condition gency plan draw possible incident sufficient protect boehringer ingelheim claim kind practise subject comprehen loss potential claim loss sive quality test regular interval product liability claim tie substantial fi nancial resource management capacity detri personnel risk mental company image event boehringer ingelheim company expose market consider product unsafe ineffective demographic change resultant risk af result effect regard risk abstract fecte lack appropriately qualified personnel risk substantial impact company busi patent protection risk ness activity risk include protection innovation trademark brand longterm planning process year patent right particular importance boehringer acquire strategic significance result counter ingelheim research company commercial pro risk mean comprehensive personnel concept tective right increasingly target attack regardless ethnic background gender religion breach take necessary precaution al offer company employee development opportuni low detect threat early stage com tie base vocational skill social competence mence appropriate countermeasure defend legal personal aptitude willingness responsibil position legal mean available ity accordance need company view risk regard concrete countermeasure describe risk garde concrete production environmental risk result fda concern quality control sectorspecific risk ingelheim production facility follow inspec boehringer ingelheim expose business risk specific tion conduct year complaint pharmaceutical industry risk change importance risk increase group significantly compare previous year contin result classify abstract ue regard abstract addition loss ex clusivity product establish market risk current focus attention effect fda associate development registration new warning letter date fda identify product risk increasingly include change problem relate compliance cgmp standard restrictive requirement relate pricing reimburse ingelheim production facility warning letter ment sale market frequently price ferre foreign particle identify pharmaceutical product subject state batch contain active pharmaceutical ingredi monitor regulation price pressure ent api boehringer ingelheim take matter cheap generic drug cause state reimbursement seriously work closely fda system reason boehringer ingelheim monitor preparation comprehensive action programme change take place sale mar deal fda concern ket closely risk report report expect development overall statement risk situation wellfille product pipeline promise study today perspective aware risk outcome product development sig conjunction risk lead nificant sale potential justifie high investment impairment company asset financial position rd plan invest research devel earning jeopardise continue exist opment new pharmaceutical product similar lev ence boehringer ingelheim el year review financial year continue renew report expect product portfolio process initiate development entry therapeutic area oncology follow marketing authorisation giotrif increase activity field diabete base treatment financial year difficult boehringer empagliflozin treatment respiratory disease ingelheim basically achieve olodaterol possible growth generate prod set achieve look ahead remain uct expect offset decline sale result schedule launch submission new prod loss exclusive right product market uct result measure take reduce cost company lead growth medium term enhance efficiency establish strong starting point come year view challenge pharmaceutical sector currently face strong growth expect positive development year review year financial year expect primarily attributable new blockbuster product sale company level pradaxa dabigatran etexilate indication stroke prevention patient atrial fibrillation net earning hand characterise product spiriva micardis sale satisfactory operating income generate adjust currency effect increase business despite increase quality control meas ure ingelheim site follow fda warning let ter significantly affect particular furthermore trajenta linagliptin treatment special effect result closure ben venue type diabete offer significant sale potential laboratory ohio usa market strategic alliance boehringer ingelheim eli lilly longterm collab ingelheim launch facility progress oration joint development marketing diabe analysis restructuring procedure pro tes active ingredient comprise active ingredi cesse fda inspection expect ent ready market year time quarter important work follow continue una increase rd expense bate ensure longterm success correspond underline strategic approach drive growth ing expenditure anticipate area product supply primarily product research development invest major challenge associate high ex good judgement intensive investigation penditure product registration make increas therapeutic benefit associate prospect success ingly difficult achieve high price innovative boehringer ingelheim annual report group management report drug justify high investment cost corporate risk research development legislative interven tion pricing prescription medicine negative impact market overall despite circumstance describe plan achieve operating income slightly level year boehringer ingelheim declare aim remain continue develop company competitively successfully independent familyowned enterprise long term sustainable organic growth take prece dence shortterm profit target confident great innovative strength base wellfilled pipeline global presence support highly qualified motivated employee key factor success achieve ambitious target continue stand vision value innovation research develop innova tion offer high medical benefit bring market aim endeavour new drug available enable doctor treat patient effectively currently possible consolidated financial statement boehringer ingelheim annual report consolidate financial statement consolidated financial statement overview major consolidated company consolidate balance sheet consolidated profit loss statement cash flow statement statement change group equity note consolidated financial tatement auditor report overview major consolidated company oovveerrvviieeww ooff tthhee mmaajjoorr ccoonnssoolliiddaatteedd ccoommppaanniieess c h boehringer sohn ag co kg boehringer ingelheim boehringer ingelheim boehringer ingelheim gmbh europe gmbh international gmbh germany p r austria p r austria r boehringer ingelheim boehringer ingelheim rcv forschungsinstitut fr molekulare pharma gmbh co kg gmbh co kg vienna pathologie gesellschaft mbh ingelheim boehringer ingelheim vienna boehringer ingelheim pharma gesmbh vienna vetmedica gmbh ingelheim belgium boehringer ingelheim czech republic scs boehringer ingelheim microparts gmbh dortmund boehringer ingelheim sro comm v brussels boehringer ingelheim prague biopharmaceutical gmbh ingelheim china p finland boehringer ingelheim boehringer ingelheim international trading shanghai finland ky espoo co ltd shanghai norway philippines boehringer ingelheim boehringer ingelheim norway ks asker phil inc manila poland boehringer ingelheim spzoo warsaw distribution p production r research development sole personally liable managing shareholder boehringer ag boehringer ingelheim annual report consolidate financial statement c h boehringer sohn grundstcksverwaltung gmbh co kg boehringer ingelheim auslandsbeteiligungs gmbh argentina r ecuador netherlands p taiwan boehringer ingelheim sa boehringer ingelheim del ecuador boehringer ingelheim bv boehringer ingelheim buenos air cia ltda quito alkmaar taiwan ltd taipei boehringer ingelheim animal health operation bv australia france p thailand alkmaar boehringer ingelheim pty ltd boehringer ingelheim boehringer ingelheim north ryde france sas paris thai ltd bangkok new zealand boehringer ingelheim brazil p greece p turkey nz ltd auckland boehringer ingelheim brasil boehringer ingelheim ellas ae boehringer ingelheim ilac quimica e farmaceutica ltda athens ticaret istanbul paulo portugal solana agro pecuaria ltda boehringer ingelheim lda indonesia p united kingdom arapongas lisbon pt boehringer ingelheim unilfarma lda lisbon boehringer ingelheim ltd indonesia jakarta bracknell canada boehringer ingelheim south africa italy p r usa p r canada ltd burlington boehringer ingelheim pty ltd boehringer ingelheim randburg boehringer ingelheim corp italia spa reggello ridgefield connecticut chile ingelheim pharmaceuticals pty ltd bidachem spa randburg boehringer ingelheim boehringer ingelheim ltda fornovo giovanni pharmaceuticals inc santiago de chile ridgefield connecticut japan p r south korea boehringer ingelheim china v p nippon boehringer ingelheim boehringer ingelheim usa corporation co ltd tokyo korea ltd seoul ridgefield connecticut boehringer ingelheim shanghai roxane laboratories inc ssp co ltd tokyo pharmaceuticals co ltd shanghai columbus ohio boehringer ingelheim china boehringer ingelheim spain p boehringer ingelheim investment co ltd shanghai vetmedica japan co ltd boehringer ingelheim vetmedica inc tokyo boehringer ingelheim vetmedica espaa sa barcelona st joseph missouri china investment co ltd shanghai boehringer ingelheim boehringer ingelheim sa boehringer ingelheim seiyaku co ltd yamagata boehringer ingelheim animal health barcelona roxane inc columbus ohio operations china co ltd taizhou boehringer ingelheim europharma sa barcelona boehringer ingelheim japan inc tokyo chemicals inc laboratorios fher sa barcelona petersburg virginia columbia p mexico p r boehringer ingelheim boehringer ingelheim sa sweden fremont inc bogot boehringer ingelheim fremont california promeco sa de cv boehringer ingelheim ab mexico city stockholm denmark p boehringer ingelheim vetmedica venezuela v boehringer ingelheim sa de cv guadalajara switzerland boehringer ingelheim danmark copenhagen caracas boehringer ingelheim schweiz gmbh basel pharmaton sa lugano consolidated financial statement c h boehringer sohn ag co kg ingelheim consolidate balance sheet asset millions eur note intangible asset tangible asset financial asset fix asset inventory account receivable asset security cash cash equivalent current asset defer charge prepaid expense defer taxis total asset liability equity millions eur note shareholder capital group reserve balance sheet currency conversion difference net income equity minority interest group equity negative difference acquisition company provision account payable liability defer charge defer taxis total liability equity explanation relevant section note consolidated financial statement boehringer ingelheim annual report consolidate financial statement c h boehringer sohn ag co kg ingelheim consolidated profit loss statement million eur note net sale change inventory internal work perform capitalise operating income total revenue material cost personnel cost amortisation intangible depreciation tangible asset operating expense operate income financial income hold income income taxis tax income taxis thirdparty share net income explanation relevant section note consolidated financial statement legal requirement disclosure shareholder personal taxis arise consolidated business activity tax expense allow taxis show withdrawal accrue group capital item consolidated profit loss statement value round millions eur disclose consolidated financial statement c h boehringer sohn ag co kg ingelheim cash flow statement million eur income taxis include thirdparty share writedownswriteup fix asset change provision pension cash flow change provision noncash income expense loss disposal fix asset change inventory change account receivable asset relate investing financing activity change trade account payable liability relate investing financing activity cash flow operating activity investment intangible asset investment property plant equipment investment noncurrent financial asset proceed disposal tangible asset proceed disposal noncurrent financial asset cash flow investing activity cash receipt fromcash payment owner minority shareholder cash proceed borrowingsrepayment loan cash flow financing activity change liquid fund cash relevant transaction change liquid fund exchange rate movement financial fund financial fund excl fixedasset security liquid fund security fix current asset source fund use fund boehringer ingelheim annual report consolidate financial statement c h boehringer sohn ag co kg ingelheim statement change group equity thereof thereof shareholders accrue currency minority currency millions eur capital group capital effect equity interest effect group equity balance withdrawal net income change balance withdrawal net income change balance shareholder capital consist equity c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg capital consist limited partner capital contribution shareholder personal taxis arise consolidated business activity show withdrawal accrue group capital item statement change equity value round millions eur disclose note consolidated financial statement c h boehringer sohn ag co kg ingelheim note consolidated financial statement principle method general principle consolidate financial statement boehringer ingelheim financial year prepare accordance section handelsgesetzbuch hgb german commercial code line requirement group accounting section et seq hgb accordance section paragraph hgb consolidated financial statement consist con solidate balance sheet consolidated profit loss statement note consolidated financial statement cash flow statement statement change equity consolidated financial statement prepare euro accordance section paragraph conjunction section hgb improve clarity consolidated financial statement individual item consolidate balance sheet consolidated profit loss statement combine item present ex plain separately note additional disclosure require individual item find note information company include consolidation parent company boehringer ingelheim group c h boehringer sohn ag co kg ingelheim boehringer ag ingelheim sole personally liable manage shareholder company c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg general partner control c h boehringer sohn ag co kg boehringer ingelheim group consist total affiliated company germany abroad addition c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg company c h boehringer sohn ag co kg directly indirectly hold majority voting right fully consolidate consolidated financial statement company include consolidation accordance section paragraph hgb reporting year individually collectively insignificant net asset financial position result operation group total sale equity net income company include consolidation account aggregated group financial statement total company classify associate accordance section paragraph hgb account immateriality ongoing restriction disposal company account boehringer ingelheim annual report consolidate financial statement article association include consolidation accordance section para graph sentence hgb total number affiliate company increase previous year company sell company found company acquire follow subsidiary exempt report disclosure obligation section para graph hgb boehringer ingelheim gmbh ingelheim boehringer ingelheim europe gmbh ingelheim boehringer ingelheim vetmedica gmbh ingelheim boehringer ingelheim secura versicherungsvermittlung gmbh ingelheim boehringer ingelheim grundstcksgesellschaft mbh ingelheim boehringer ingelheim finanzierung gmbh ingelheim boehringer ingelheim rd beteiligung gmbh ingelheim boehringer ingelheim venture fund gmbh ingelheim exempt duty prepare disclose annual financial statement management report ac cordance hgb provision corporation section b hgb c h boehringer sohn ag co kg ingelheim c h boehringer sohn grundstcksverwaltung gmbh co kg ingelheim boehringer ingelheim pharma gmbh co kg ingelheim c h boehringer selbstmedikation kg ingelheim boehringer ingelheim veterinary research center gmbh co kg hanover consolidation method inventory fix asset receivables liability income expense item transaction company include consolidation eliminate debt consolidation accordance section hgb elimination intercompany profit accordance section hgb con solidation income expense accordance section hgb revaluation method section hgb applied acquisition accounting firsttime consolida tion subsidiary firsttime consolidation occur date company subsidiary carrying share hold parent company offset correspond equity subsidiary equity carry fair value asset liability prepay expense defer income special reserve include consolidated financial statement time con solidation remain balance offset capitalise goodwill note consolidated financial statement currency translation asset liability result foreign currency transaction translate middle spot ex change rate balance sheet date realisation principle section paragraph conjunction section paragraph nd halfsentence hgb historical cost convention section paragraph conjunction section paragraph sentence hgb comply remain ing term year consolidated financial statement financial statement foreign subsidiary domicile state outside euro zone denominate foreign currency convert euro accord ance section hgb modify closing rate method modify closing date rate method asset equity liability item annual financial state ment prepare foreign currency translate euro middle spot exchange rate closing date exception equity translate historical rate item profit loss statement translate euro average rate result translation difference report consolidated equity reserve difference equity currency transla tion important currency group develop follow report year basis eur yearend rate average annual rate dollar japanese yen pound sterle canadian dollar boehringer ingelheim annual report consolidate financial statement accounting policy fix asset acquire intangible asset tangible asset carry cost straightline amortisation deprecia tion respectively line technical economic circumstance base follow useful life intangible asset year building year technical equipment machinery year equipment operate office equipment year straightline depreciation amortisation consolidated financial statement anticipate permanent impairment show extraordinary writeoff direct cost material labour cost appropriate portion material labour overhead depreciation fix asset cause pro duction take account determine production cost capitalise intangible asset limit useful life goodwill firsttime consolidation share usually amortise period year useful life year apply goodwill boehringer ingelheim korea ltd acquire past experience product sale market business condition boehringer ingelheim korea ltd show present true fair view financial asset essentially include shareholder right security loan carry low cost fair market value impair current asset prepaid expense inventory carry low cost fair market value raw material consumable supply capitalise low average acquisition price fair market value balance sheet date finish good work progress measure production cost basis individual calcula tion take account directly attributable cost material direct labour cost special direct cost appropriate share production material overhead depreciation good resale value lower purchase cost fair market value identifiable risk inventory asset arise aboveaverage storage period diminish marketability low replacement cost take account appropriate valuation adjustment note consolidated financial statement inventory value lossfree ie discount recognise expect sale price cost incur receivables asset recognise cost allowance specific risk general credit risk lowinter noninterestbeare receivables term year discount security classify current asset include security recognise low cost quotedmarket price report date cash cash equivalent recognise low cost fair market value defer charge prepaid expense accordance section paragraph hgb include expense pay advance certain period balance sheet date defer charge accordance section paragraph hgb include proceed income certain period balance sheet date negative difference acquisition company negative difference acquisition company recognise result net asset company acquire march august exceed purchase price value negative difference acquisition company amount eur million january creased acquisition company acquire august amount eur million lease negative difference acquisition company eur million financial year eur million show operate income release negative difference acquisition company line amortisation excess net asset time acqui sition period amortisation currently estimate year group reserve group reserve include retain earning consolidate subsidiary prior year consolida tion entry affect earning relate prior year provision tax provision provision include uncertain liability expect loss executory con tract carry require settle obligation base reasonable business judge ment accordance prudence principle ie include future cost price increase provision remain term year discount matchedterm average market interest rate seven year accordance rckstellungsabzinsungsverordnung german regula tion discount provision boehringer ingelheim annual report consolidate financial statement liability liability recognise settlement defer taxis calculate defer taxis temporary quasipermanent difference accounting carrying amount asset liability prepay expense defer income tax carrying amount tax loss carryforward amount result tax benefit expense time reversal measure tax rate specific respective consolidated company discount dif ference consolidation measure accordance section hgb measure ing companyspecific tax rate time expect reversal difference defer tax asset loss carryforward take account likely year defer tax asset liability report netted note consolidated financial statement note consolidated balance sheet intangible asset acquire goodwill advance total concession payment million eur similar right procurementmanufacture cost balance currency conversion difference addition consolidation addition disposal reclassification balance currency conversion difference addition consolidation addition disposal reclassification balance accumulate depreciation balance currency conversion difference addition consolidation addition writeup disposal reclassification balance currency conversion difference addition consolidation addition writeup disposal reclassification balance book value book value boehringer ingelheim annual report consolidate financial statement tangible asset land technical advance total building facility facility payment machine operate construction million eur equipment progress procurementmanufacture cost balance currency conversion difference addition consolidation addition disposal reclassification balance currency conversion difference addition consolidation addition disposal reclassification balance accumulate depreciation balance currency conversion difference addition consolidation addition writeup disposal reclassification balance currency conversion difference addition consolidation addition writeup disposal reclassification balance book value book value note consolidated financial statement financial asset investment loan investment investment total affiliate affiliate relate security loan million eur company company company procurementmanufacture cost balance currency conversion difference addition consolidation addition disposal reclassification balance currency conversion difference addition consolidation addition disposal reclassification balance accumulate amortisation balance currency conversion difference addition consolidation addition writeup disposal reclassification balance currency conversion difference addition consolidation addition writeup disposal reclassification balance book value book value previous year loan item include loan shareholder boehringer ingelheim annual report consolidate financial statement inventory million eur raw material supply unfinished product finish product good resale advance payment supplier account receivable asset residual residual term term millions eur year year trade account receivable receivables affiliate company receivables related company asset asset item include receivables shareholder eur million previous year eur million receivable affiliate company previous year exclusively consist receivables loan receivables related company essentially consist trade account receivable provision million eur pension provision tax provision provision note consolidated financial statement provision pension similar obligation provision pension similar obligation determine basis actuarial calculation project unit credit method take account future adjustment salarie pension addition local biometric datum eg prof heubeck g mortality table germany pension obliga tion significant country calculate basis follow actuarial parameter december germany usa japan discount rate salary increase pension increase provision pension similar obligation discount average market interest rate remain term year accordance german regulation discount provision november interest rate discount significant foreign pension obligation japan determine comparable parameter line german regulation discount provision november plan asset intend solely cover pension similar obligation unavailable credi tor cover asset mean section paragraph sentence hgb measure fair mar ket value essentially derive stock market price offset underlie pension similar obligation fair market value plan asset balance sheet date eur million correspond present value pension similar obligation eur million gain loss plan asset interest expense relate pension similar obligation offset accord ance section paragraph sentence hgb total eur million gain plan asset eur million interest expense relate pension similar obligation include financial income boehringer ingelheim annual report consolidated financial statement account payable residual term residual term million eur year year year year bank loan account payable trade account payable advance payment account payable affiliate company account payable relate company liabilitie taxis eur million social security liability eur million previous year liability secure mortgage similar collateral right balance sheet date end year liability shareholder eur million previous year eur million payable affiliate company consist payable loan amount eur million previous year eur million trade account payable amount eur million previous year eur million note consolidated financial statement note consolidated profit loss statement structure consolidated profit loss statement base total cost format net sale business business segment million eur prescription medicine consumer health care animal health biopharmaceutical industrial customer sale geographic region millions eur europe germany americas usa asia australia africa japan operating income operating income include income currency translation eur million previous year eur million material cost million eur cost raw material supply good resale expenditure service boehringer ingelheim annual report consolidate financial statement personnel cost millions eur salary wage social benefit retirement benefits retirement benefit interest effect measurement provision pension similar obligation show separate item financial income average headcount production administration marketing sale research development apprentice amortisation intangible asset depreciation tangible asset amortisation intangible fix wasset depreciation fix tangible asset include extraordinary writedown eur million previous year eur million operating expense operating expense include expense currency translation eur million previous year eur million operating expense essentially include thirdparty service area research development med icine marketing plus administrative expense fee contribution commission rent freight ex pense thirdparty repair note consolidated financial statement financial income millions eur interest expense relate pension similar obligation provision interest expense similar expenditure interest expense similar expenditure amortisation loss disposal financial asset shortterm investment income investment security longterm loan interest income similar proceed hold income million eur writeoff financial asset income relate company affiliate company tax million eur income taxis defer taxis current income taxis essentially include cost corporation trade tax company include consolidation result conclusion profit transfer agreement significant german corporation clude trade corporation tax group parent company c h boehringer sohn ag co kg january income taxis shareholder c h boehringer sohn ag co kg curre operating income report consolidated profit loss statement trade income tax company concern fully consolidated german partnership show tax expense total defer tax asset amount eur million balance sheet date defer tax asset essentially relate different carrying amount provision fix asset inventory defer tax liability recognise eur million mainly relate difference car rye amount tangible asset inventory provision boehringer ingelheim annual report consolidate financial statement net income net income positively influence priorperiod operating income essentially versal provision eur million previous year eur million negatively influence priorperiod operating expense eur million previous year eur million note cash flow statement cash flow statement show cash cash equivalent cash longterm security invest ment classify current asset sell time boehringer ingelheim group change result cash inflow outflow report year accordance german accounting standard cash flow statement gas break accord cash flow operating activity cash flow invest financing activity change balance sheet item affiliate company include translate average rate year balance sheet cash cash equivalent carry closing rate effect exchange rate change cash cash equivalent show separately financial year eur million receive interest eur million previous year eur mil lion pay interest eur million previous year eur million pay taxis note consolidated financial statement disclosure contingent liabilitie eur million liability guarantee bill cheque guarantee warranty grant security thirdparty liability risk utilisation individual contingent liability estimate follow risk utilisation guarantee liability bank affiliate company rate low ac count solid net asset financial position result operation subsidiary question financial commitment million eur rental leasing obligation purchase commitment obligation rental lease agreement eur million previous year eur million eur million previous year eur million relate longterm rental agreement sub sidiarie include consolidation purpose lease agreement low capital commitment compare buy property absence resale risk risk arise term lease long possible fully utilise property indication time financial commitment include future expense followup investment investment ini tiate future major repair balance sheet date purchase commitment include future cash vestment eur million previous year eur million offbalance sheet transaction derivative financial instrument hedge owe extensive international structure boehringer ingelheim group highly dependent de velopment world currency interest rate hedge risk particularly emerge good service finance currency forwards option generally currency risk interest rate swap option interest rate risk use derivative financial instrument organisational process set internal guide line strict separation trading processing documentation control risk position regularly track analysed measure special consolidated financial report position enter periodically reevaluate monitor fair market value derivative boehringer ingelheim annual report consolidate financial statement financial instrument calculate standard market measurement method currency interest forwards net present value method currency interest option recognise option pricing model basis market datum available balance sheet date currency interest option recognise fair market value exceeding option premium pay receive derecognised maturity provision eur million recognise currency forward include hedge accounting negative fair market value currency balance sheet date line imparity principle positive fair market value currency recognise balance sheet date follow derivative financial instrument include hedge accounting nominal value market value millions eur foreign exchange forward contract requirement hedge account foreign exchange forward contract highly probable fore cast transaction accordance section hgb meet foreign exchange forward contract recognise balance sheet line net hedge presentation method follow accounting policy apply recognition hedge accordance section hgb economic hedge account hedge accounting hedge recognise foreign currency net highly probable forecast transaction currency forwards match forecast net cash flow term maturity nominal foreign currency macro hedge highly probable forecast transaction income outgoing payment plan sale purchase derive company plan expost analysis planning show plan transaction highly probable critical term maturity nominal foreign currency match oppose change value hedge item hedge instrument fully offset effective hedge assume prospectively retrospectively critical term match method exclusively measure pro spective retrospective hedge effectiveness note consolidated financial statement december hedge highly probable forecast net cash flow recognise follow january december net cash flow million eur fx forward contract millions eur nominal value nominal value market value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn gbp gbp gbp january december net cash flow million eur fx forward contract millions eur nominal value nominal value market value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn gbp gbp gbp january december net cash flow million eur fx forward contract millions eur nominal value nominal value market value usd usd usd jpy jpy jpy january net cash flow million eur fx forward contract millions eur nominal value nominal value market value jpy jpy jpy boehringer ingelheim annual report consolidate financial statement hedge foreign currency risk correlate relative change exchange rate planning date realisation date forecast transaction currency appreciate depreciate euro foreign currency risk plus minus eur million hedge balance sheet date floatingrate loan amount eur million interest rate swap matching amount match maturity conclude hedge interest rate risk associate involve transform floatingrate loan portion fix interest rate use hedge accounting micro hedge oppose change value hedge item hedge instrument fully offset balance sheet date interest rate swap include accrue interest fair market value minus eur million carrying equal defer accrue interest eur million report liability bank net hedge presentation method research development expense millions eur research development expense research development expense capitalise include cost phase iv clinical study total auditor fee total fee charge auditor financial year eur million eur million relate audits financial statement eur million assurance valuation service eur million service auditor report auditor report audit consolidated financial state conduct audit consolidate finan ment prepare ch boehringer sohn ag cial statement accordance article co kg ingelheim comprise balance sheet hgb german commercial code german income statement statement change eq generally accept standard audit fi uity cash flow statement note con nancial statement promulgate institut der solidate financial statement wirtschaftsprfer institute public auditor group management report business year germany idw standards require january december prepa plan perform audit misstate ration consolidate financial statement ment materially affect presentation group management report accordance net asset financial position result opera german commercial law responsibility tion consolidate financial statement manage director manage cor accordance german principle proper ac porate general partner responsibility counting group management report express opinion consolidated financial detect reasonable assurance knowledge statement group management report business activity economic legal base audit environment group expectation possible misstatement take account determination audit procedure effec tiveness accountingrelate internal control system evidence support disclo sure consolidate financial statement group management report examine pri marily test basis framework audit audit include assess annual fi nancial statement company include consolidation determination company include consolidation accounting consolidation principle significant estimate manage director manage corporate general partner evaluate overall presentation consoli date financial statement group manage ment report believe audit provide reasonable basis opinion boehringer ingelheim annual report consolidate financial statement exception follow qualification audit lead reservation contrary article nos b hgb total remuneration grant member member board manage director member supervisory body pension provision recognize recognize member board manage director disclose note con solidated financial statement opinion base finding audit qualification mention con solidate financial statement comply legal requirement consolidate financial state ment true fair view net asset financial position result operation group accordance german principle proper accounting group management report consistent consolidated financial statement comply legal requirement provide suitable view group position suitably present opportunity risk future development frankfurt main february pricewaterhousecooper aktiengesellschaft wirtschaftsprfungsgesellschaft philip marshall dr ulrich strk wirtschaftsprfer wirtschaftsprfer german certify german certify public accountant public accountant product portfolio boehringer ingelheim annual report product portfolio product portfolio selection brand prescription medicine consumer health care animal health brand prescription medicine respiratory disease chronic obstructive pulmonary disease copd bronchial asthma bronchial asthma prevalent bronchial asthma chronic inflammatory disor chronic disease affect lung frequent der airways chronic inflammation air cause morbidity premature death worldwide way accompany airway hyperresponsive ness lead narrow airways copd recurrent episode wheeze breathlessness copd chronic disease lung cough particularly night early hour airways narrow lead limitation morning know asthma airflow cause shortness breath re trigger genetic environmental factor piratory symptom airflow limitation e g allergen viral infection variable partially reversible usually worsen gradually breathe difficulty occur early stage time destruction lung tissue mainly affect disease airflow limitation normally ful ing alveolus gas exchange excessive ly reversible patient free symptom mucus airway induce chronic cough con attack contrast copd asthma tribute burden disease complaint occur childhood main reason copd stressful patient lung emphysema chronic bronchitis main manifestation copd copd cause continuous damage lung result inhale pollutant primarily ciga rette smoke environmental pollutant air irritant lung course copd disease occur second half human life characterise acceler ate loss lung function compare normal age e occasional sudden worsen symptom function refer acute exacerbation boehringer ingelheim annual report product portfolio indication brand name active ingredient chronic obstructive spiriva tiotropium bromide maintenance treatment patient pulmonary disease copd forvent copd chronic obstructive pulmonary disease include chronic bronchitis emphysema maintenance treatment associate dyspnoea prevention exacerbation chronic obstructive striverdi olodaterol maintenance bronchodilator treatment pulmonary disease copd patient chronic obstructive pulmonary disease copd bronchospasm associate combivent ipratropium bromide management reversible broncho reversible obstructive salbutamol spasm associate obstructive airway disease airway disease patient require bronchodilator chronic obstructive atrovent ipratropium bromide bronchodilator maintenance treat pulmonary disease copd ment bronchospasms associated chronic bronchitis chronic obstructive pulmonary disease asthma copd include chronic bronchitis emphysema asthma bronchial asthma berodual ipratropium prevention treatment symptom chronic bronchitis bronchodual bromide chronic obstructive airway disorder duovent fenoterol reversible airflow limitation bronchial asthma especially chronic bronchitis em physema bronchial asthma berotec fenoterol symptomatic treatment acute asthma attack condition versible airway narrow e g chronic obstructive bronchitis prophylaxis exerciseinduce asthma bronchial asthma inflammide budesonide chronic control symptom bron chial asthma bronchial asthma alesion epinastine prophylactic treatment bronchial allergic rhinitis flurinol asthma prophylaxis symptomatic treatment allergic rhinitis brand prescription medicine cardiovascular disease cardiovascular disease lead cause acute myocardial infarction death country increase acute myocardial infarction heart attack prevalence acute event occur thrombus clot suddenly prevent blood flow area heart stroke muscle blood flow restore quickly stroke rapidly develop loss brain af fecte section heart muscle perma function blockage blood flow nently damage heart attack leading cause affect brain tissue ischaemia death develop country lack blood supply cause thrombosis embolism bleeding result affect area brain unable function damage quickly permanent untreated stroke acute event require emergency diagnosis intervention worldwide stroke lead cause death longterm disability symptom transient ischaemic attack tia similar stroke minute hour tia precede stroke emergency medical care subsequent preventive treatment necessary boehringer ingelheim annual report product portfolio indication brand name active ingredient essential hypertension micardis telmisartan treatment essential hypertension cardiovascular prevention micardisplus telmisartan hydrochlorothiazide reduction risk myocar micardi plus dial infarction heart attack stroke micardis hct death cardiovascular cv cause comicardis patient year age old high risk develop major cv event unable ace inhibitor usa reduction cardiovascular mor bidity patient manifest athero thrombotic cardiovascular disease tory coronary heart disease stroke peripheral arterial disease type diabete mellitus document tar organ damage eu hypertension twynsta telmisartan amlodipine treatment hypertension micamlo antihypertensive agent initial micardis amlo therapy patient likely need multi micardis anlo ple antihypertensive agent achieve micardis duo blood pressure goal usa micardis duo addon therapy adult patient adequately control blood pressure amlodipine replacement therapy adult patient receive telmisartan amlodipine separate tablet eu secondary prevention aggrenox dipyridamole prevention stroke follow stroke transient ischaemic agrenox acetylsalicylic acid stroke transient ischaemic attack attack tia asasantin asasantin retard hypertension catapresan clonidine form high blood pressure catapre cause phaeochromocytoma catapressan acute ischaemic stroke actilyse alteplase fibrinolytic treatment acute ischae acute myocardial infarction actilyse cathflo mg mic stroke acute myocardial infarction acute massive pulmonary acute massive pulmonary embolism embolism catheter clearance thrombotic catheter clearance occlusion thrombotic occlusion brand prescription medicine cardiovascular disease continue hypertension cardiovascular disease atrial fibrillation hypertension refer high blood pressure patient atrial fibrillation af high risk chronic disease blood pressure develop blood clot cause disa chronically elevate hypertension bling stroke clot travel brain af jor risk factor stroke heart attack heart failure common type arrhythmia associate chronic renal failure hypercoagulable state predispose stroke systemic embolism prevent billion people worldwide affect effective chronic anticoagulation hypertension prevalence essential hyperten sion increase steadily age world popu venous thromboembolism lation age preventive strategy term patient undergo orthopaedic surgery con lifestyle change far fail prevalence siderable risk develop deep vein thrombosis hypertension set increase leg potentially fatal pulmonary embolism know venous thromboembolism hypertension major risk factor cardiovascular vte long term thromboembolic event morbidity mortality organ risk pri recur chronic venous insufficiency andor marily heart main blood vessel brain pulmonary hypertension occur prevent vte kidney primary goal antihyper event consequence patient receive tensive treatment prevent cardiovascular event kind thromboprophy laxis heart attack stroke finally reduce cardiovascular mortality cardiovascular disease cvd responsible nearly death worldwide number cause death proper control treatable risk factor disease vital prevention cardiovascular event boehringer ingelheim annual report product portfolio indication brand name active ingredient acute myocardial infarction metalyse tenecteplase fibrinolytic treatment acute myocar dial infarction hypertension motens lacidipine treatment essential hypertension stroke prevention atrial pradaxa dabigatran prevention stroke blood clot fibrillation pradaxar etexilate patient abnormal heart rhythm prazaxa atrial fibrillation primary prevention venous pradaxa dabigatran primary prevention venous thrombo thromboembolic event pradaxar etexilate embolic event vte adult orthopaedic surgery elective total hip knee replacement surgery prescription medicine metabolic disease diabete estimate number case reach type diabetes chronic progressive condition million cause longterm complication control longterm complication diabete include ne phropathy lead renal failure potential year million death worldwide link risk dialysis retinopathy potential loss vi directly longterm effect diabetes type sion increase incidence stroke cardiovas diabete common form account cular disease peripheral neuropathy risk case develop world foot ulcer foot leg amputation auto affect million people worldwide impose nomic neuropathy cause gastrointestinal genitouri enormous burden health care system globally nary cardiovascular symptom sexual dys effective prevention management function oncology cancer threat global health esti lung cancer disease mate million new case cancer diag different subtype small cell lung cancer nose worldwide million people die sclc nonsmall cell lung cancer nsclc malignant disease common newly different molecular genetic aberration diagnose cancer type lung cancer mutation present tumour identi breast cancer colorectal cancer fie focus molecular change spe cific specific subtype lung cancer target lung cancer therapy effective treat lung cancer bronchogenic carcinoma refer ment harmful normal cell malignant abnormal cell growth inside lung tis reduce effect normal cell sue form cluster tumour com mon cancer estimate million new case mutation egf receptor epidermal growth year worldwide smoking primary factor receptor egfr erbb occur cause disease contribute cas caucasian asian patient es recently incidence lung cancer adenocarcinoma type mutation oc nonsmoker woman increase lung cancer cur frequently exclusively woman negative prognosis million death nonsmoker treat tyrosine year represent cancer death lung kinase inhibitor tkis erbb blocker cancer sign unspecific year receptor family giotrifgilotrif afatinib appear late diagnosis advanced stage disease result negative prognosis lung cancer patient survive year follow diagnosis boehringer ingelheim annual report product portfolio indication brand name active ingredient type diabete mellitus trajenta linagliptin treatment type diabete mellitus tradjenta improve glycaemic control adult trazenta monotherapy metformin trayenta tolerate contraindicated combination therapy type diabete mellitus jentadueto linagliptin metformin hydrochloride treatment type diabete mellitus trayenta duo improve glycaemic control adult trajenta duo treatment metformin lead sufficient control patient treat trajenta metformin indication brand name active ingredient nonsmall cell lung cancer giotrif afatinib treatment patient meta nsclc gilotrif static nonsmall cell lung cancer nsclc tumor activate epidermal growth factor receptor egfr mutation brand prescription medicine disease central nervous system mental neurological disease depression primary symptom r esult lack parkinson disease significantly impact patient neurotransmitter dopamine distinct area family substantial burden human brain society restless leg syndrome rls parkinson disease restless leg syndrome rls common neurolog parkinson disease pd degenerative disorder ical disorder characterise uncontrollable urge central nervous system patient usually leg primarily occur evening notice motor symptom like hand tremor shake night hour usually accompany un sign disease progress pleasant painful sensation tually include shake arm leg head leg disturb sleep result daytime motor symptom develop time tiredness sleepiness sensation feel deep include stiffness result loss facial leg describe creep crawl expression gradual slow loss motion ing ache freeze patient suffer nonmotor symptom associate pd dementia depression sleep disorder infectious disease hiv infectionaid acquire immune deficiency syndrome aid set symptom infection result damage human immune system cause human immunodeficiency virus hiv untreated condition progressively reduce effective ness immune system leave individual susceptible opportunistic infection tumour baby infect mother risk get virus pregnancy childbirth breastfeed boehringer ingelheim annual report product portfolio indication brand name active ingredient parkinson disease pd sifrol pramipexole symptomatic treatment idiopathic restless leg syndrome rls mirapex parkinson disease mirapex er monotherapy combination mirapexin levodopa symptomatic treatment pexola idiopathic moderate severe restless leg syndrome sleep disorder lendormin brotizolam shortterm treatment disorder lindormin initiate maintain sleep indication brand name active ingredient hivaid viramune nevirapine available tablet suspension viramune xr adult child combina tion therapy hiv infection country prevention mothertochild transmission hiv pregnant woman take antiretroviral therapy time labour prolong release tablet oncedaily dose combination therapy hivaids aptivus tipranavir capsule oral solution coadmini tere mg ritonavir indi cat combination antiretroviral treatment hivinfecte patient evidence viral replication treatment experience infect hiv strain resistant pro tease inhibitor consumer health care cough cold mucosolvan ambroxol bisolvon mucoviral bisolviral antiviral nasal spray bromhexine indicate secretolytic launch spray contain iota therapy broncho pulmonary disease associate carrageenan extract natural red sea abnormal mucus secretion impair mucus weed apply nasally iotacarrageenan act transport like protective layer inhibit infection nasal epithelial cell cold virus virus cough common symptom clinical m dock specific receptor cell sur portance frequent reason consulting face clinical trial use mucoviralbisolviral doctor visit pharmacy clinical symptom show reduce viral load pa cough expectoration lead develop tient nasal secretion reduce duration ment drug affect respiratory mucus e cold mucoactive agents boxagrippal launch germany mucosolvan promote mucus clearance fa follow successful switch prescription cilitate expectoration ease productive cough overthecounter otc medicine status cold allow patient breathe freely deeply remedy combine antiinflammatory pain reliev available different product form er nsaid ibuprofen oral decongestant mulation pseudoephedrine hydrochloride treat troublesome symptom cold block nose ambroxol active metabolite bromhexine sinuse combination headache fever synthetic derivative herbal coldrelate pain active ingredient vasicine extract plant species adhatoda vasica ambroxol mucoactive drug property include secretolytic secretomotoric action restore physio logical clearance mechanism respiratory tract play important role bodys natural defence mechanism ambroxol stimu late synthesis release surfactant type ii pneumocytes bisolvon available age group market bromhexine contain formulation bisolvon show increase proportion bronchi al secretion make easily expectorate bromhexine enhance mucus transport ducing mucus viscosity activate ciliated epithelium boehringer ingelheim annual report product portfolio indication brand name active ingredient acute chronic broncho mucosolvan ambroxol secretolytic therapy acute chronic pulmonary disease mucosan bronchopulmonary disease associate surbronc abnormal mucus secretion m lasolvan pair mucus transport mucopect acute chronic broncho bisolvon bromhexine secretolytic therapy acute chronic pulmonary disease bisolvon chesty bronchopulmonary disease associate bisolvonlinctus abnormal mucus secretion m pair mucus transport irritable cough silomat dmp dextrometorphan symptomatic treatment irritable non bisoltussin productive cough bisolvon dry bisolsek bisolvon antitusivo common cold mucoviral iotacarrageenan antiviral treatment common cold bisolviral sustain moisturi surbroncviraltm sation nasal mucosa common cold boxagrippal ibuprofen symptomatic treatment nasal conge pseudoephedrine tion combination headache andor fever consumer health care sore throat mucoangin ambroxol indicate pain relief addition secretolytic activity ambroxol acute sore throat pain sore throat hall potent inhibitor neuronal sodium channel mark acute pharyngitis usually cause viral mucoangin show local anaes infection infection rule selflimite thetic effect describe late patient normally recover couple day explain confirm recent work bothersome patient con tinuous pain throat maximise swallow main goal treatment reduce pain pain brand thomapyrin comprise product type headache migraine thomapyrin posi treatment acute pain mild intermediate intensity tione expert treatment headache line extension available thomapyrin classic thomapyrin classic core product normal headache thomapyrin intensiv compose triple combination acetylsalicylic strong headache thomapyrin effervescent acid paracetamol caffeine component tablet galenic alter native suppress pain synergistically interaction painrelate molecular mechanism alongside thomapyrin boehringer ingelheim sult thomapyrin classic offer fast superior offer analgesic combination ibuprofen efficacy compare single component allylisopropylacetylurea dehydrate caffeine prove stateoftheart magnesium oxide japan tradename clinical study eve mono active ingredient metami zol brazil tradename anador reason triple combination recom mend national international medical society choice acute treatment tension boehringer ingelheim annual report product portfolio indication brand name active ingredient sore throat mucoangin ambroxol pain relief acute sore throat lysopadol lysopain dol isodinemint zerinol gola indication brand name active ingredient pain thomapyrin acetylsalicylic acid adult adolescent old thomapyrin classic paracetamol caffeine year acute treatment mild thomapyrin intensiv moderate headache migraine attack aura treat ment tensiontype headache available germany pain eve ibuprofen adult old year reduc eve allylisopropylacetylurea dehydrate tion fever temporary relief mild eve quick caffeine magnesium oxide moderate ache pain associate headache menstrual pain oth er body pain available japan eve quick pain anador metamizol adult adolescent old lisalgil year acute treatment mild nolotil moderate headache available brazil consumer health care gastrointestinal disease gastrointestinal portfolio offer modic product buscopan act directly site brand dulcolax surulac laxoberal abdominal pain relax smooth muscle guttalax buscopan heartburn gastrointestinal biliary urinary genital tract brand zantac buscopan antiacido gastol mean buscopan relieve abdominal pain directly treat main cause abdominal cramp constipation common problem dulcolax spasm lead overthecounter otc laxative remedy constipation relief worldwide today buscopan available line exten sion mono variant different combination dulcolax tablet special enteric comfort analgesic paracetamol ibuprofen metam coating ensure active ingredient izoldipyrone different formulation tablet dulcolax tablet bisacodyl take drop suppositorie syrup solution intrave need act colon colon co nous injection lonic juice activate key ingredient relieve consti pation stimulate natural umbrella brand buscopan offer buscofem ment bowel provide gentle predictable menstrual pain relief buscopan relief hour tablet take antiacido b uscopan reflusso heartburn go bed provide relief relief morning extend gastrointestinal portfolio product dulcolax range include vaprino new selfmedication product dulcoease dulcoenema dulcogas diarrhoea active ingredient racecadotril effective form acute diarrhoea surulac constipation brand japan reduce exceed secretion gut consumer offer surulac laxative tablet change gastrointestinal transit time motility laxoberal guttalax brand offer vaprino provide new mode action consumer constipation relief flexible dosage enable fast relief diarrhoea format drop block bowel abdominal cramping pain discomfort com mon ailment approximately person worldwide suffer regular basis buscopan antispasmodic product active ingredient hyoscine butylbromide product basically natural substance extract duboisia plant specie scopolamine hyoscine chemically modify quaternary ammonium compound h yoscine butylbromide antispas boehringer ingelheim annual report product portfolio indication brand name active ingredient constipation dulcolax bisacodyl laxative use patient suffer surulac bisacodyl sennoside constipation preparation diagnostic procedure pre post operative treatment condition require defecation facilitate constipation laxoberal sodium picosulphate laxative use case constipation laxoberon condition require defeca guttalax tion facilitate dulcolax np dulcodrop dulcogotas gas bloat dulcogas simethicone fastacting granule relieve gas bloat prevent flatulence abdominal pain buscopan hyoscine butylbromide treatment relief abdominal buscapina cramping pain discomfort heartburn zantac ranitidine relief heartburn associate acid buscopan antiacido indigestion sour stomach prevent heartburn associate acid indige tion sour stomach bring certain food beverage available usa acute diarrhoea vaprino racecadotril treatment symptom acute diar rhoea adult consumer health care vitamin supplement pharmaton multivitamin mineral supple pharmaton matruelle indicate woman ment brand develop support physical man actively plan pregnant pregnant wom tal wellbee range product adapt en breastfeed woman contain important need different target audience develop micronutrient mother baby vitamin work harmony body mineral omega fatty acid cover creased need substance particular pharmaton vitality range product adult period help protect embryo contain select blend vitamin minerals nal neural tube disease foetus iron trace element plus standardised ginseng extract folic acid anaemia pregnancy g main target indication exhaustion tiredness decrease concentration mental alert pharmaton cardioactive product design ness case deficient nutrition loss adult year age contain blend vita appetite debility illness convalescence min mineral combine omega fatty acid numerous clinical study show regular help maintain cardiovascular health intake pharmaton positive effect mental physical performance wellbee pharmaton kiddi range product design child contain select vitamin mineral essential amino acid lysine important dur ing period growth recommend preventive treatment vitamin deficiency boehringer ingelheim annual report product portfolio indication brand name active ingredient tiredness decrease con pharmaton standardised ginseng improve general wellbeing centration case defi pharmaton vitality extract vitamin cient nutrition loss appe pharmaton geriavit minerals trace tite debility illness geriatric pharmaton elements convalescence gericomplex pharmaton complex pharmaton fizzi pharmaton active life increase demand pharmaton kiddi vitamin increase demand vitamin mineral vitamin childhood mineral amino acid especially amino acid period growth preventive treatment case vitamin deficiency e g stricted diets convalescence loss appetite follow illness infection surgery prophylaxis iron folic pharmaton vitamin minerals woman pregnancy acid deficiency matruelle trace element prevent deficiency symptom pregnancy omega fatty acid cover increase need vita docosahexaenoic min mineral trace element dha acid dha provide protection embryonal neural tube disease foetus prophylaxis iron folic acid anae mia pregnancy maintenance pharmaton vitamin mineral trace element help maintain cardiovascular health cardio vascular health cardioactive fish oil omega fatty acid rich cover daily need vitamin pharmaton epa dha mineral trace element fish oil coractive omega fatty acid rich epa pharmaton protect dha act complementary daily nutrition consumer health care leg vein health brand antistax boehringer capsule offer effective treatment describe ingel heim market range product develop symptom antistax help fluid prevention treatment symptom attribut flow small venous vessel venule able chronic venous insufficiency com surround tissue normal level mon symptom venous insufficiency observable standing sit long time consumer varicose vein oedema low leg heavy tired leg sensation tension red vine leaf extract active ingredient tingling cramp pain antistax capsule antistax product antiinflammatory effect tablet scientifically prove help maintain work endothelium inside venule healthy leg vein circulation sealing inside reduce swell sensation pain heaviness heavy aching tired leg occur long period stand sit increase product available antistax range include end day summer outdoor antistax tablet antistax capsule antistax temperature rise antistax tablet antistax creme cosmetic product antistax leg chilling gel urological disease benign prostate hyperplasia bph refer symptom lut frequent nighttime enlargement prostate middleage urination urge urinate hour weak elderly man lead low urinary tract flow feel unfinished urinating boehringer ingelheim annual report product portfolio indication brand name active ingredient chronic venous insufficiency antistax red vine leaf extract prevention treatment symptom chronic venous insufficiency varicose veins leg oedema painful swollen leg tingle leg tired heavy leg heavy tired leg antistax cool care symptomatic treatment heavy tired substance red vine leg leaf extract indication brand name active ingredient benign prostate hyperplasia flomax relief tamsulosin treatment low urinary tract symp bph tom lut common condition call benign prostate hyperplasia bph available uk animal health foodproducing animal swine infectious respiratory disease infectious enteric disease ingelvac circoflex singledose piglet enterisol ileitis vaccine vaccine control porcine circovirus disease ileitis cause lawsonia intracellularis license pcvd vaccine provide significant reduction improve weight gain reduce growth varia mortality acute phase pcvd bility associate disease enterisol ileitis improve growth rate chronic phase help reduce total antimicrobial use pork disease ingelvac circoflex protect minimal production systemic adverse reaction injection site swelling mix ingelvac circoflex ingelvac mycoflex approve european commis sion ingelvac prrs mlv license active m munisation respiratory reproductive form porcine reproductive respiratory syn drome prrs ingelvac mycoflex license active immu nisation pig enzootic pneumonia ep singledose regimen advance adju vant system provide longlaste effective protection prove highchallenge situation foodproduce animal poultry volvac umbrella brand boehringer bacterial disease like avian influenza infectious ingelheim animal health poultry vaccine range bronchitis newcastle disease nfectious bursal dis consist wide range live inactivate vac ease egg drop syndrome avian coryza cine broiler layer vaccine provide volvac vaccine allow bird express protection bird viral potential increase wellbee boehringer ingelheim annual report product portfolio indication brand name active ingredient infectious respiratory ingelvac circoflex recombinant vaccine active immunisation pig disease porcine circovirus age week porcine type pcv circovirus type reduce mortality clinical sign include weight loss lesion lymphoid tissue asso ciate porcine circovirus disease pcvd addition vaccination show reduce pcv nasal shed viral load blood lymphoid tissue duration viraemia infectious respiratory ingelvac prrs mlv attenuate live vaccine active immunisation swine disease prrs virus age week respiratory reproductive form prrs virus infection porcine reproduc tive respiratory syndrome infectious respiratory ingelvac mycoflex inactivate vaccine active immunisation pig disease mycoplasma age week lung hyopneumoniae lesion follow infection myco plasma hyopneumoniae infectious enteric disease enterisol ileitis attenuate live active immunisation pig vaccine lawsonia age week intestinal intracellularis lesion cause lawsonia intracellula ris infection reduce growth vari ability loss weight gain associat ed disease indication brand name active ingredient viral bacterial volvac polyvalent attenuate live inac vaccination healthy chicken disease poultry tivate vaccine contain antigen disease cause include vaccination avian influ antigen common disease enza newcastle disease responsible loss egg production avian coryza egg drop layer affect health syndrome infectious broiler chicken bronchitis infectious bursal disease bacterium anatis animal health foodproducing animal cattle mastitis mastitis inflammation udder dairy cattle mainly cause bacterial infection preven tion treatment mastitis animal key produce healthy milk minimise symptom associate clinical situation ubrolexin today product treatment acute bacterial mastitis ubrostar tomorrow prevent mastitis dryingoff dairy cattle end lactation period mamyzin effective injectable antimicrobial treatment acute mastitis metacam reduce acute pain associate syndrome boehringer ingelheim annual report product portfolio indication brand name active ingredient mastitis mamyzin penethamate hydroiodide treatment mastitis dairy cow mastitis benestermycin penethamate hydroiodide treatment subclinical mammary ubrostar benethamine penicillin infection present dryingoff framycetin sulphate mastitis ubrolexin cefalexin monohydrate treatment clinical mastitis lactate kanamycin monosulphate dairy cow cause bacteria mastitis today cephapirin sodium intramammary infusion lactat ing cow available usa mastitis tomorrow cephapirin benzathine intramammary infusion dry cow available usa animal health foodproducing animal cattle continue pain inflammatory disease control pain support restoration metacam member class nonsteroidal farm animal use metacam con antiinflammatory drug nsaid address venient inflict minimal stress animal need maintain profitability con lowvolume oneshot dosage cern animal welfare animal production longacte nature outstanding metacam license use cattle suffer efficacy control inflammatory symptom respiratory disease indicate calf af help minimise loss inflammation fecte diarrhoea adjunctive therapy maintain profitability animal suffer treatment mastitis lactate cow disease time metacam effectively companion animal horse main horse product focus therapeutic laminitis change body conformation lack area respiratory disease lameness colic performance treatment p rascend life hormonal disorder long ventipulmin treatment acute chronic vetera vaccine vaccine portfolio respiratory disease airway obstruction include multiple convenient combination disease bronchospasm andor mucus accumulation protection horse young month contribute factor improve mucociliary clear age vaccine protect ance desirable ventipulmin infectious organism include influenza herpe adjunctive therapy chronic obstructive pul west nile virus tetanus enable monary disease copd acute subacute customise protection horse limited chronic respiratory allergic condition needle injection vetera vaccine formulat ed utilise ultrafil purification technology prascend indicate treatment pituitary remove extraneous protein par intermedia dysfunction ppid allow horse immune system focus know equine cushing disease prascend relevant antigen substitute lack dopamine pituitary par intermedia clinical sign hypertrichiosis boehringer ingelheim annual report product portfolio indication brand name active ingredient pain inflammatory metacam meloxicam alleviation inflammation pain disease muscoloskeletal disorder dog cat pig horse surgery dog cat pig colic horse adjunctive treatment diarrhoea respiratory disease acute mastitis dehorning cattle mastitis metritisagalactia syndrome pig cattle infectious disease pyramid attenuate vaccine bovine vaccination healthy dairy beef presponse rhinotracheitisvirus diarrhoea cattle aid prevention disease parainfluenza respiratory syncytial caused include antigen virus mannheimia haemolytica canada toxoid indications brand name active ingredient acute chronic obstruc ventipulmin clenbuterol respiratory disease attend bron tive respiratory disease chial spasm like subacute chronic bronchitis bronchiolitis chronic obstructive pulmonary disease copd auxillary acute bronchitis pneumonia bronchia pituitary par intermedia prascend pergolide mesylate treatment clinical sign asso dysfunction ppid ciate pituitary par intermedia dysfunction ppid know equine cushing disease way combination vetera eastern western venezuelan vaccination healthy horse vaccine common encephalomyelitis tetanus aid prevention disease cause disease horse west nile virus include antigen canada equine herpes virus equine influenza viruse animal health companion animal small animal main small animal product address major prozinc aqueous protamine zinc pzi sus chronic disease heart failure kidney disease pension recombinant human insulin epilepsy osteoarthritis reduce hyperglycaemia cat diabete mellitus new class heart treatment term inodilator vetmedin show signifi semintra angiotensin ii antagonist cantly improve clinical sign extend life expec newly approve reduction proteinuria associ tancy dog congestive heart failure origin ate chronic kidney disease ckd cat ating dilate cardiomyopathy valvular semintra decrease mean arterial blood pressure insufficiency mitral andor tricuspid regurgitation proteinuria available oral solution vetmedin work complementary mode action open blood vessel take pexion new alternative treatment blood away heart lower epilepsy active substance imepitoin pri pressure heart reduce work marily inhibit seizure potentiation gabaa heart pump blood dog receptormediate inhibitory effect neuron body time vetmedin direct pexion approve reduction generalise effect heart muscle helping beat strong seizure idiopathic epilepsy poten pump blood efficiently tial safety benefit exist standard treatment metacam nonsteroidal antiinflammatory drug nsaid available oral suspension tablet injectable solution dog oral sus pension injectable solution cat dog indication include alleviation inflammation pain acute chronic musculoskeletal disorder reduction postoperative pain follow surgery cat indication clude alleviation inflammation pain acute chronic musculoskeletal disorder alleviation mild moderate postoper ative pain follow surgical procedure variety formulation offer veterinarian owner flexibility use formulation prefer manage level inflammation pain associate license indication boehringer ingelheim annual report product portfolio indication brand name active ingredient congestive heart failure vetmedin pimobendan treatment canine congestive heart failure originate dilatative cardio myophathy valvular insufficiency mitral andor tricuspid regurgitation pain inflammatory metacam meloxicam dog indication include alle disease viation inflammation pain acute chronic musculoskeletal dis order reduction post operative pain follow surgery cat indication include alle viation inflammation pain acute chronic musculoskeletal dis order alleviation mild moderate postoperative pain follow e surgical procedure feline diabete mellitus prozinc protamine zinc reduction hyperglycaemia recombinant hyperglycaemiaassociated clinical sign human insulin cat diabete mellitus currently available usa feline chronic kidney disease semintra telmisartan reduction proteinuria associated chronic kidney disease ckd cat canine idiopathic epilepsy pexion imepitoin reduction frequency generalise seizure idiopathic epilepsy dog careful evaluation alternative treatment option c h boehringer sohn ag co kg ingelheim comparison balance sheet financial datum comparison balance sheet million eur asset december intangible asset tangible asset financial asset fix asset inventory account receivable incl defer charge defer taxis liquid fund current asset incl deffered charge defer taxis total asset liability equity december shareholder capital reserve incl currency conversion difference net income total equity minority interest group equity negative difference acquisition company provision incl defer taxis liability incl defer charge total liability incl defer taxis defer charge total liability equity summary select financial datum net sale operating income operating income net sale income taxis income taxis net sale return shareholder equity equity ratio cash flow financial fund personnel cost personnel cost net sale average number employee research development cost r net sale investment tangible asset depreciation tangible asset comparison balance sheet million eur asset december intangible asset tangible asset financial asset fix asset inventory account receivable incl defer charge defer taxis liquid fund current asset incl deffered charge defer taxis total asset liability equity december shareholder capital reserve incl currency conversion difference net income total equity minority interest group equity negative difference acquisition company provision incl defer taxis liability incl defer charge total liability incl defer taxis defer charge total liability equity summary select financial datum net sale operating income operating income net sale income taxis income taxis net sale return shareholder equity equity ratio cash flow financial fund personnel cost personnel cost net sale average number employee research development cost r net sale investment tangible asset depreciation tangible asset query comment contact boehringer ingelheim gmbh binger strasse ingelheim germany telephone fax contact corporate division communication email webmasterboehringeringelheimcom internet wwwboehringeringelheimcom issue boehringer ingelheim gmbh concept design layout mpm gmbh corporate communication solution wwwdigitalagenturmpmde photo lukas beck p james horan p lorenzo vannucci p print sddeutsche verlagsgesellschaft ulm copyright boehringer ingelheim gmbh right reserve annual report reproduce transmit form mean electronic photocopy permission write boehringer ingelheim gmbh figure party annual report base datum available time financial statement draw upwwwboehringeringelheimcom annualreportboehringeringelheimcom